

John J V McMurray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5419095/publications.pdf>

Version: 2024-02-01

1,257
papers

220,319
citations

45

186
h-index

26

438
g-index

1315
all docs

1315
docs citations

1315
times ranked

93576
citing authors

#	ARTICLE	IF	CITATIONS
1	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	13.9	7,537
2	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, e147-e239.	1.2	7,017
3	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	1.0	5,689
4	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
5	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). <i>European Heart Journal</i> , 2012, 33, 1665-1701.	1.0	5,247
6	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012, 33, 1787-1847.	1.0	5,233
7	Angiotensin-converting Enzyme Inhibition versus Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2014, 371, 993-1004.	13.9	5,052
8	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2010, 31, 2369-2429.	1.0	4,635
9	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1995-2008.	13.9	4,108
10	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016, 18, 1609-1678.	0.7	3,523
11	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Circulation</i> , 2013, 128, 1810-1852.	1.6	2,807
12	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	1.0	2,767
13	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Heart Journal</i> , 2008, 29, 2388-2442.	1.0	2,656
14	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. <i>Lancet</i> , 2003, 362, 777-781.	6.3	2,584
15	Dapagliflozin in Patients with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1436-1446.	13.9	2,523
16	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. <i>New England Journal of Medicine</i> , 2011, 364, 11-21.	13.9	2,491
17	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Circulation</i> , 2013, 128, e240-327.	1.6	2,335
18	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.	2.9	2,307

#	ARTICLE	IF	CITATIONS
19	Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. <i>New England Journal of Medicine</i> , 2003, 349, 1893-1906.	13.9	2,240
20	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2009, 361, 2019-2032.	13.9	2,110
21	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. <i>Lancet</i> , The, 2010, 375, 735-742.	6.3	2,064
22	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. <i>Lancet</i> , The, 2003, 362, 767-771.	6.3	1,978
23	Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. <i>New England Journal of Medicine</i> , 2005, 352, 1071-1080.	13.9	1,950
24	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. <i>European Journal of Heart Failure</i> , 2008, 10, 933-989.	2.9	1,893
25	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015, 373, 2247-2257.	13.9	1,856
26	Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. <i>European Heart Journal</i> , 2006, 28, 230-268.	1.0	1,802
27	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2089-2099.	13.9	1,754
28	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet</i> , The, 2003, 362, 759-766.	6.3	1,752
29	Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, 1653-1659.	13.9	1,732
30	Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2004, 351, 1285-1295.	13.9	1,712
31	Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2008, 359, 2456-2467.	13.9	1,663
32	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. <i>Lancet</i> , The, 2003, 362, 772-776.	6.3	1,623
33	Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1609-1620.	13.9	1,485
34	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2851-2906.	1.0	1,394
35	Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2010, 12, 1360-1420.	0.7	1,360
36	Rosuvastatin in Older Patients with Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2007, 357, 2248-2261.	13.9	1,330

#	ARTICLE	IF	CITATIONS
37	A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. <i>American Journal of Medicine</i> , 2002, 113, 359-364.	0.6	1,328
38	Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. <i>Lancet, The</i> , 2009, 373, 2125-2135.	6.3	1,243
39	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2018, 392, 1519-1529.	6.3	1,179
40	Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2012, 367, 2204-2213.	13.9	1,145
41	Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 365, 32-43.	13.9	1,133
42	Targeted Anticytokine Therapy in Patients With Chronic Heart Failure. <i>Circulation</i> , 2004, 109, 1594-1602.	1.6	1,062
43	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 1387-1395.	6.3	990
44	Biochemical detection of left-ventricular systolic dysfunction. <i>Lancet, The</i> , 1998, 351, 9-13.	6.3	967
45	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology, the</i> , 2019, 7, 776-785.	5.5	961
46	Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. <i>European Heart Journal</i> , 2013, 34, 1404-1413.	1.0	921
47	Increased Mortality after Dronedarone Therapy for Severe Heart Failure. <i>New England Journal of Medicine</i> , 2008, 358, 2678-2687.	13.9	901
48	More "malignant" than cancer? Five-year survival following a first admission for heart failure. <i>European Journal of Heart Failure</i> , 2001, 3, 315-322.	2.9	885
49	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2013, 369, 2492-2503.	13.9	844
50	Predictors of mortality and morbidity in patients with chronic heart failure. <i>European Heart Journal</i> , 2006, 27, 65-75.	1.0	822
51	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	2.9	820
52	Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2006, 113, 671-678.	1.6	817
53	Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 40-47.	1.2	809
54	Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. <i>Lancet, The</i> , 2018, 391, 572-580.	6.3	808

#	ARTICLE	IF	CITATIONS
55	Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2010, 12, 767-778.	2.9	787
56	Heart failure with preserved left ventricular systolic function. <i>Journal of the American College of Cardiology</i> , 2004, 43, 317-327.	1.2	756
57	Heart failure. <i>Lancet, The</i> , 2005, 365, 1877-1889.	6.3	756
58	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, e1-e88.	0.6	754
59	Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2012, 14, 341-343.	2.9	737
60	Rosiglitazone Evaluated for Cardiovascular Outcomes – An Interim Analysis. <i>New England Journal of Medicine</i> , 2007, 357, 28-38.	13.9	729
61	Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. <i>New England Journal of Medicine</i> , 2005, 352, 2581-2588.	13.9	721
62	Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients. <i>Circulation</i> , 2005, 112, 3738-3744.	1.6	678
63	An epidemiological study of pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2007, 30, 104-109.	3.1	668
64	SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. <i>Diabetologia</i> , 2018, 61, 2108-2117.	2.9	641
65	Obesity Is a Risk Factor for Severe COVID-19 Infection. <i>Circulation</i> , 2020, 142, 4-6.	1.6	595
66	Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. <i>European Journal of Heart Failure</i> , 2010, 12, 423-433.	2.9	593
67	Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 447-456.	1.2	591
68	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1477-1490.	13.9	588
69	Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. <i>Lancet, The</i> , 1997, 350, 829-833.	6.3	582
70	Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure. <i>Circulation</i> , 2002, 106, 920-926.	1.6	582
71	Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. <i>European Journal of Heart Failure</i> , 2011, 13, 347-357.	2.9	580
72	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015, 385, 351-361.	6.3	562

#	ARTICLE	IF	CITATIONS
73	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. <i>Circulation</i> , 2015, 131, 54-61.	1.6	552
74	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008, 29, 1377-1385.	1.0	549
75	Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 1482-1487.	1.6	528
76	Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. <i>International Journal of Cardiology</i> , 2013, 167, 1807-1824.	0.8	523
77	Iron deficiency: an ominous sign in patients with systolic chronic heart failure. <i>European Heart Journal</i> , 2010, 31, 1872-1880.	1.0	515
78	Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1997-2004.	1.2	507
79	Randomised controlled trial of specialist nurse intervention in heart failure. <i>BMJ: British Medical Journal</i> , 2001, 323, 715-718.	2.4	477
80	The current cost of heart failure to the National Health Service in the UK. <i>European Journal of Heart Failure</i> , 2002, 4, 361-371.	2.9	471
81	Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003. <i>Circulation</i> , 2009, 119, 515-523.	1.6	468
82	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. <i>Nature Communications</i> , 2020, 11, 163.	5.8	466
83	Expert consensus document on β -adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1341-1362.	1.0	465
84	Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2013, 368, 1210-1219.	13.9	462
85	Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009, 11, 433-443.	2.9	449
86	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 653-662.	5.5	437
87	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 853-872.	2.9	434
88	Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 1146-1155.	13.9	433
89	A Comparison of the Reproducibility and the Sensitivity to Change of Visual Analogue Scales, Borg Scales, and Likert Scales in Normal Subjects During Submaximal Exercise. <i>Chest</i> , 1999, 116, 1208-1217.	0.4	432
90	Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1463-1476.	13.9	430

#	ARTICLE	IF	CITATIONS
91	Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum Cardiomyopathy. <i>Circulation</i> , 2010, 121, 1465-1473.	1.6	429
92	2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. <i>European Heart Journal</i> , 2010, 31, 2677-2687.	1.0	427
93	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. <i>European Heart Journal</i> , 2018, 39, 26-35.	1.0	426
94	Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. <i>European Journal of Heart Failure</i> , 2009, 11, 130-139.	2.9	423
95	Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction. <i>Circulation</i> , 2011, 124, 2491-2501.	1.6	418
96	Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. <i>Lancet</i> , The, 2005, 366, 2005-2011.	6.3	410
97	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2019, 393, 1937-1947.	6.3	408
98	Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. <i>American Heart Journal</i> , 2010, 159, 331-339.	1.2	407
99	Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2010, 362, 228-238.	13.9	395
100	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	13.9	381
101	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. <i>Lancet</i> , The, 2020, 396, 121-128.	6.3	376
102	Anemia and Its Relationship to Clinical Outcome in Heart Failure. <i>Circulation</i> , 2004, 110, 149-154.	1.6	371
103	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Circulation</i> , 2018, 137, 961-972.	1.6	368
104	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2013, 15, 1062-1073.	2.9	358
105	Declining Risk of Sudden Death in Heart Failure. <i>New England Journal of Medicine</i> , 2017, 377, 41-51.	13.9	355
106	Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. <i>Circulation</i> , 2004, 110, 2618-2626.	1.6	347
107	Dilated cardiomyopathy. <i>Nature Reviews Disease Primers</i> , 2019, 5, 32.	18.1	347
108	Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure. <i>Circulation: Heart Failure</i> , 2008, 1, 17-24.	1.6	340

#	ARTICLE	IF	CITATIONS
109	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1353.	3.8	340
110	Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 479-487.	2.2	336
111	Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2007, 9, 684-694.	2.9	335
112	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. <i>European Heart Journal</i> , 2015, 36, 1990-1997.	1.0	335
113	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020, 141, 352-361.	1.6	335
114	Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2009.	3.8	330
115	Body Mass Index and Prognosis in Patients With Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 627-636.	1.6	328
116	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>European Journal of Heart Failure</i> , 2009, 11, 170-177.	2.9	326
117	Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. <i>New England Journal of Medicine</i> , 2019, 380, 447-458.	13.9	321
118	Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2011, 13, 115-126.	2.9	318
119	Economics of chronic heart failure. <i>European Journal of Heart Failure</i> , 2001, 3, 283-291.	2.9	315
120	Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2004, 364, 347-354.	6.3	315
121	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <i>European Journal of Heart Failure</i> , 2015, 17, 544-558.	2.9	315
122	Risk Prediction in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 440-446.	1.9	303
123	2010 Focused Update of ESC Guidelines on device therapy in heart failure. <i>Europace</i> , 2010, 12, 1526-1536.	0.7	297
124	The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. <i>Lancet, The</i> , 2011, 378, 676-683.	6.3	295
125	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018, 20, 1230-1239.	2.9	295
126	Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction. <i>Circulation</i> , 2010, 121, 1393-1405.	1.6	290

#	ARTICLE	IF	CITATIONS
127	The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. <i>BMJ</i> , The, 2015, 350, h910-h910.	3.0	289
128	Investigation Into the Sources of Superoxide in Human Blood Vessels. <i>Circulation</i> , 2000, 101, 2206-2212.	1.6	287
129	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 22-31.	5.5	287
130	Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1663-1671.	0.4	286
131	Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. <i>Heart</i> , 2011, 97, 740-747.	1.2	282
132	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009, 11, 119-129.	2.9	281
133	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1495-1539.	1.2	276
134	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2006, 152, 86-92.	1.2	275
135	Renal Effects and Associated Outcomes During Angiotensin-Nepriylsin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 489-498.	1.9	272
136	Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2425-2436.	1.2	271
137	Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas. <i>Circulation</i> , 2006, 114, 1028-1035.	1.6	267
138	Developing Therapies for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112.	1.9	267
139	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675.	2.9	264
140	Longitudinal and Circumferential Strain Rate, Left Ventricular Remodeling, and Prognosis After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1812-1822.	1.2	263
141	Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design. <i>Journal of Cardiac Failure</i> , 1999, 5, 276-282.	0.7	260
142	Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 843-851.	5.5	260
143	Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	260
144	Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15,000 middle-aged men and women (the Renfrew-Paisley study). <i>European Heart Journal</i> , 2006, 27, 96-106.	1.0	259

#	ARTICLE	IF	CITATIONS
145	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 333-340.	5.5	258
146	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 1956-1964.	13.9	257
147	Serum Soluble ST2. <i>Journal of the American College of Cardiology</i> , 2010, 55, 243-250.	1.2	256
148	Cognitive Impairment and Heart Failure: Systematic Review and Meta-Analysis. <i>Journal of Cardiac Failure</i> , 2017, 23, 464-475.	0.7	255
149	SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. <i>Diabetologia</i> , 2016, 59, 1333-1339.	2.9	254
150	Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction. <i>Circulation</i> , 2005, 111, 3411-3419.	1.6	251
151	Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. <i>Journal of Cardiac Failure</i> , 2005, 11, 12-20.	0.7	250
152	Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease The Task Force on ACE-inhibitors of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1454-1470.	1.0	249
153	Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1598-1603.	1.2	249
154	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 877-886.	5.5	245
155	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 141, 90-99.	1.6	244
156	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2020, 141, 338-351.	1.6	244
157	Antiarrhythmic effect of carvedilol after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005, 45, 525-530.	1.2	242
158	Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients. <i>Circulation</i> , 2004, 110, 2180-2183.	1.6	241
159	Albuminuria in chronic heart failure: prevalence and prognostic importance. <i>Lancet</i> , 2009, 374, 543-550.	6.3	239
160	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 471-482.	1.9	238
161	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021, 143, 516-525.	1.6	237
162	Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2007, 115, 3111-3120.	1.6	235

#	ARTICLE	IF	CITATIONS
163	Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2006, 113, 986-994.	1.6	229
164	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2016, 388, 2895-2903.	6.3	229
165	Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2008, 1, 582-591.	2.3	227
166	Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 569-577.	1.6	219
167	Heart failure and socioeconomic status: accumulating evidence of inequality. <i>European Journal of Heart Failure</i> , 2012, 14, 138-146.	2.9	218
168	Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 27-35.	1.6	216
169	Iron status in patients with chronic heart failure. <i>European Heart Journal</i> , 2013, 34, 827-834.	1.0	212
170	Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure. <i>Circulation</i> , 2005, 112, 48-53.	1.6	211
171	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1021-1034.	1.2	211
172	What Works In Chronic Care Management: The Case Of Heart Failure. <i>Health Affairs</i> , 2009, 28, 179-189.	2.5	209
173	Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1585-1593.	1.2	204
174	Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2016, 374, 1521-1532.	13.9	204
175	Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. <i>European Heart Journal</i> , 2010, 31, 824-831.	1.0	203
176	Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy. <i>Circulation: Heart Failure</i> , 2014, 7, 51-58.	1.6	203
177	Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. <i>European Journal of Heart Failure</i> , 2015, 17, 925-935.	2.9	203
178	Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction. <i>Circulation</i> , 2004, 110, 1572-1578.	1.6	201
179	Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1850-1859.	1.2	200
180	Trends in hospitalization for heart failure in Scotland, 1990â€“1996. An epidemic that has reached its peak?. <i>European Heart Journal</i> , 2001, 22, 209-217.	1.0	198

#	ARTICLE	IF	CITATIONS
181	Heart Failure Care in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. <i>PLoS Medicine</i> , 2014, 11, e1001699.	3.9	198
182	Usefulness of Right Ventricular Fractional Area Change to Predict Death, Heart Failure, and Stroke Following Myocardial Infarction (from the VALIANT ECHO Study). <i>American Journal of Cardiology</i> , 2008, 101, 607-612.	0.7	197
183	Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. <i>Circulation</i> , 2013, 127, 2166-2176.	1.6	196
184	Explanation for the Decline in Coronary Heart Disease Mortality Rates in Auckland, New Zealand, Between 1982 and 1993. <i>Circulation</i> , 2000, 102, 1511-1516.	1.6	195
185	Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. <i>Circulation</i> , 2010, 122, 597-602.	1.6	195
186	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <sc>DELIVER</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1217-1225.	2.9	195
187	The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure. <i>Archives of Internal Medicine</i> , 2008, 168, 1699.	4.3	194
188	Impaired left atrial function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1096-1103.	2.9	194
189	A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1696-1704.	1.2	193
190	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 298-309.	1.6	193
191	Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. <i>Lancet, The</i> , 2020, 396, 1745-1757.	6.3	192
192	N-Terminal Pro-“B-Type Natriuretic Peptide for Risk-“Assessment in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2274-2284.	1.2	191
193	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in-“Acute-“Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1444-1455.	1.2	191
194	Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. <i>European Journal of Heart Failure</i> , 2007, 9, 83-91.	2.9	188
195	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. <i>European Heart Journal</i> , 2015, 36, 2576-2584.	1.0	187
196	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to <sc>CHARM</sc>-Preserved. <i>European Journal of Heart Failure</i> , 2014, 16, 33-40.	2.9	186
197	Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. <i>Lancet, The</i> , 2014, 383, 1059-1066.	6.3	186
198	Epidemiology of Heart Failure and Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction: Prevalence, Clinical Characteristics, and Prognostic Importance. <i>American Journal of Cardiology</i> , 2006, 97, 13-25.	0.7	185

#	ARTICLE	IF	CITATIONS
199	Diabetes, left ventricular systolic dysfunction, and chronic heart failure. <i>European Heart Journal</i> , 2008, 29, 1224-1240.	1.0	184
200	Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009, 158, 896-901.e3.	1.2	184
201	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 535-542.	2.9	184
202	Heart failure in a cold climate. <i>Journal of the American College of Cardiology</i> , 2002, 39, 760-766.	1.2	183
203	Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. <i>European Journal of Heart Failure</i> , 2008, 10, 149-156.	2.9	183
204	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	2.9	182
205	Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 656-665.	2.3	182
206	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. <i>Kidney International</i> , 2021, 100, 215-224.	2.6	182
207	Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. <i>European Journal of Heart Failure</i> , 2017, 19, 1154-1163.	2.9	181
208	Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. <i>European Journal of Heart Failure</i> , 2016, 18, 1193-1202.	2.9	180
209	Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008, 371, 1761-1768.	6.3	178
210	Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	178
211	Seasonal variations in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 654-664.	6.1	178
212	The Lys198Asn Polymorphism in the Endothelin-1 Gene Is Associated With Blood Pressure in Overweight People. <i>Hypertension</i> , 1999, 33, 1169-1174.	1.3	177
213	Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 571-578.	1.6	177
214	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 1749-1758.	6.3	175
215	Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1228-1234.	2.9	173
216	Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFREF. <i>Journal of the American College of Cardiology</i> , 2019, 73, 795-806.	1.2	173

#	ARTICLE	IF	CITATIONS
217	Selecting patients for cardiac resynchronization therapy: electrical or mechanical dyssynchrony?. European Heart Journal, 2006, 27, 1270-1281.	1.0	170
218	Predominance of Heart Failure in the Heart of Soweto Study Cohort. Circulation, 2008, 118, 2360-2367.	1.6	168
219	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. Journal of the American College of Cardiology, 2019, 73, 29-40.	1.2	168
220	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrology Dialysis Transplantation, 2020, 35, 274-282.	0.4	168
221	Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. European Heart Journal, 1998, 19, 481-489.	1.0	167
222	Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. European Journal of Heart Failure, 2012, 14, 473-479.	2.9	167
223	Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal, 2008, 29, 2641-2650.	1.0	164
224	Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. American Heart Journal, 2000, 140, 727-750.	1.2	162
225	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 2017, 38, 1132-1143.	1.0	160
226	The Dapagliflozin And Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. European Journal of Heart Failure, 2019, 21, 1402-1411.	2.9	159
227	What Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?. Journal of the American College of Cardiology, 2012, 60, 2349-2356.	1.2	157
228	Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2014, 2, 116-124.	5.5	157
229	Intensive glycaemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. American Heart Journal, 2011, 162, 938-948.e2.	1.2	156
230	Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circulation, 2009, 120, 2188-2196.	1.6	155
231	The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. International Journal of Obesity, 2014, 38, 1110-1114.	1.6	155
232	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, The, 2019, 394, 1169-1180.	6.3	155
233	A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart, 2007, 93, 606-612.	1.2	154
234	Incidence and Predictors of Hyperkalemia in Patients With Heart Failure. Journal of the American College of Cardiology, 2007, 50, 1959-1966.	1.2	153

#	ARTICLE	IF	CITATIONS
235	Renal effects of the angiotensin receptor neprilysin inhibitor <scp>LCZ696</scp> in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 510-517.	2.9	153
236	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2017, 135, 724-735.	1.6	153
237	2010 Focused Update of ESC Guidelines on device therapy in heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 1143-1153.	2.9	152
238	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020, 41, 2379-2392.	1.0	151
239	Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. <i>European Heart Journal</i> , 2007, 28, 829-835.	1.0	150
240	Health-Related Quality of Life Outcomes in PARADIGM-HF. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	150
241	The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2006, 47, 726-733.	1.2	149
242	Results of a reevaluation of cardiovascular outcomes in the RECORD trial. <i>American Heart Journal</i> , 2013, 166, 240-249.e1.	1.2	149
243	How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?. <i>Circulation</i> , 2021, 143, 875-877.	1.6	149
244	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012, 33, 2782-2795.	1.0	148
245	Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGMâ€HF</scp>). <i>European Journal of Heart Failure</i> , 2014, 16, 817-825.	2.9	148
246	Vasodilator Effects of Endothelin-Converting Enzyme Inhibition and Endothelin ET A Receptor Blockade in Chronic Heart Failure Patients Treated With ACE Inhibitors. <i>Circulation</i> , 1996, 94, 2131-2137.	1.6	148
247	Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1785-1795.	1.2	146
248	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 1505-1514.	1.6	145
249	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. <i>Circulation</i> , 2020, 141, 100-111.	1.6	145
250	Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>European Heart Journal</i> , 2012, 33, 2290-2296.	1.0	144
251	Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2011, 162, 900-906.	1.2	143
252	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. <i>JAMA Cardiology</i> , 2017, 2, 79.	3.0	143

#	ARTICLE	IF	CITATIONS
253	Failure of Women's Hearts. <i>Circulation</i> , 1999, 99, 2334-2341.	1.6	142
254	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. <i>Circulation</i> , 2016, 133, 2254-2262.	1.6	142
255	Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 271-277.	1.2	141
256	Corrigendum to: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [<i>Eur Heart J</i> 2008;29:2388-2442]. <i>European Heart Journal</i> , 2010, 31, 624-624.	1.0	141
257	Lipid-Modifying Therapies and Risk of Pancreatitis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 804.	3.8	140
258	Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014, 35, 224-232.	1.0	140
259	Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 8-17.	1.9	140
260	Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl. <i>Journal of Cardiac Failure</i> , 2014, 20, 953-958.	0.7	139
261	The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. <i>Heart</i> , 2016, 102, 1342-1347.	1.2	139
262	Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. <i>Circulation</i> , 2018, 138, 2774-2786.	1.6	139
263	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1264-1272.	1.2	139
264	Echocardiography and lung ultrasonography for the assessment and management of acute heart failure. <i>Nature Reviews Cardiology</i> , 2017, 14, 427-440.	6.1	138
265	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2858-2873.	1.2	138
266	Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996. <i>European Heart Journal</i> , 2001, 22, 693-701.	1.0	137
267	Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2013, 6, 451-460.	1.6	136
268	Heart Failure and Chronic Obstructive Pulmonary Disease. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2127-2138.	1.2	135
269	The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition. <i>JAMA Cardiology</i> , 2017, 2, 939.	3.0	135
270	Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. <i>Kidney International</i> , 2000, 57, 1100-1106.	2.6	134

#	ARTICLE	IF	CITATIONS
271	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. <i>Circulation: Heart Failure</i> , 2010, 3, 314-325.	1.6	134
272	High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 52-61.	1.2	133
273	Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. <i>American Journal of Cardiology</i> , 1990, 65, 1261-1262.	0.7	132
274	Gender and survival: a population-based study of 201,114 men and women following a first acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2001, 38, 729-735.	1.2	130
275	Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. <i>European Heart Journal</i> , 2011, 32, 1227-1234.	1.0	130
276	Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2016, 1, 666.	3.0	130
277	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002744.	1.6	130
278	Angiotensin Receptorâ€“Nepriylsin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021, 385, 1845-1855.	13.9	130
279	The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and Design. <i>Journal of Cardiac Failure</i> , 2005, 11, 576-585.	0.7	129
280	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGMâ€“HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 337-341.	2.9	129
281	New Therapeutic Options in Congestive Heart Failure: Part I. <i>Circulation</i> , 2002, 105, 2099-2106.	1.6	128
282	Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case-Control Study From the U.K. General Practice Research Database. <i>Diabetes Care</i> , 2010, 33, 1213-1218.	4.3	128
283	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020, 142, 1040-1054.	1.6	128
284	A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2005, 7, 1059-1069.	2.9	127
285	An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. <i>European Heart Journal</i> , 2004, 25, 1911-1919.	1.0	126
286	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , 2015, 36, 1536-1546.	1.0	126
287	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021, 42, 3727-3738.	1.0	125
288	Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 547-554.	5.5	124

#	ARTICLE	IF	CITATIONS
289	Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD. <i>American Journal of Kidney Diseases</i> , 2011, 58, 717-728.	2.1	123
290	Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2013, 1, 21-28.	1.9	123
291	Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 590-595.	1.6	123
292	Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1056-1061.	1.2	122
293	Statins and chronic heart failure: do we need a large-scale outcome trial?. <i>Journal of the American College of Cardiology</i> , 2002, 39, 1567-1573.	1.2	122
294	Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A ₁ , high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. <i>European Journal of Heart Failure</i> , 2009, 11, 281-291.	2.9	120
295	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 499.	3.0	120
296	Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , 2003, 5, 261-270.	2.9	119
297	Public awareness of heart failure in Europe: first results from SHAPE. <i>European Heart Journal</i> , 2005, 26, 2413-2421.	1.0	118
298	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2059-2071.	1.2	118
299	Impaired endothelial function in isolated human uremic resistance arteries. <i>Kidney International</i> , 2001, 60, 1077-1082.	2.6	117
300	Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study. <i>European Heart Journal</i> , 2008, 30, 56-65.	1.0	117
301	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	1.6	117
302	Lung Ultrasound in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 849-858.	1.9	116
303	Rationale Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. <i>American Heart Journal</i> , 2005, 149, 408-413.	1.2	115
304	The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. <i>European Journal of Heart Failure</i> , 2009, 11, 855-862.	2.9	114
305	Geographic variations in the PARADIGM-HF heart failure trial. <i>European Heart Journal</i> , 2016, 37, 3167-3174.	1.0	114
306	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2490-2500.	1.2	114

#	ARTICLE	IF	CITATIONS
307	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1130.	3.0	114
308	Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. <i>American Heart Journal</i> , 2000, 139, 609-617.	1.2	113
309	Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. <i>European Journal of Heart Failure</i> , 2011, 13, 107-114.	2.9	113
310	Influenza Vaccination in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 152-158.	1.9	112
311	Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 2325-2335.	13.9	112
312	Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. <i>European Journal of Heart Failure</i> , 2005, 7, 710-721.	2.9	111
313	Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2006, 8, 591-598.	2.9	111
314	Indications and practical approach to non-invasive ventilation in acute heart failure. <i>European Heart Journal</i> , 2018, 39, 17-25.	1.0	111
315	Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. <i>European Journal of Heart Failure</i> , 2012, 14, 268-277.	2.9	110
316	High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 625-634.	1.6	110
317	Terminology and definition of changes renal function in heart failure. <i>European Heart Journal</i> , 2014, 35, 3413-3416.	1.0	108
318	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 2313-2324.	13.9	108
319	Endothelium-Derived Hyperpolarizing Factor. <i>Circulation</i> , 2001, 103, 1702-1708.	1.6	107
320	Adherence to medication according to sex and age in the CHARM programme. <i>European Journal of Heart Failure</i> , 2009, 11, 1092-1098.	2.9	107
321	Design of the Reduction of Events with Darbeoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. <i>European Journal of Heart Failure</i> , 2009, 11, 795-801.	2.9	107
322	Temporal Trends and Patterns in Mortality After Incident Heart Failure. <i>JAMA Cardiology</i> , 2019, 4, 1102.	3.0	107
323	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1700-1711.	0.4	107
324	Coenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1196-1204.	1.2	105

#	ARTICLE	IF	CITATIONS
325	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. <i>European Heart Journal</i> , 2015, 36, 1958-1966.	1.0	105
326	Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. <i>European Journal of Heart Failure</i> , 2015, 17, 242-247.	2.9	105
327	Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?. <i>Circulation: Heart Failure</i> , 2013, 6, 727-732.	1.6	103
328	Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) – Added trial. <i>American Heart Journal</i> , 2006, 151, 985-991.	1.2	102
329	Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. <i>European Heart Journal</i> , 2008, 29, 748-756.	1.0	102
330	Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2009, 11, 292-298.	2.9	102
331	Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency. <i>Journal of the American College of Cardiology</i> , 2014, 63, 853-871.	1.2	102
332	Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction. <i>Circulation</i> , 2005, 112, 3391-3399.	1.6	101
333	Troponin I in acute decompensated heart failure: insights from the ASCEND – HF study. <i>European Journal of Heart Failure</i> , 2012, 14, 1257-1264.	2.9	101
334	Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. <i>Journal of the American College of Cardiology</i> , 2016, 68, 241-248.	1.2	101
335	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020, 41, 3787-3797.	1.0	101
336	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021, 143, 2129-2142.	1.6	101
337	Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 329-340.	1.9	100
338	Age, sex, and social trends in out-of-hospital cardiac deaths in Scotland 1986 – 95: a retrospective cohort study. <i>Lancet</i> , 2001, 358, 1213-1217.	6.3	99
339	The clinical relevance of adrenomedullin: a promising profile?. , 2004, 103, 179-201.		99
340	<sc>EURObservational</sc> Research Programme: a worldwide registry on peripartum cardiomyopathy (<sc>PPCM</sc>) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on <sc>PPCM</sc>. <i>European Journal of Heart Failure</i> , 2014, 16, 583-591.	2.9	99
341	Effect of Rosuvastatin on Repeat Heart Failure Hospitalizations. <i>JACC: Heart Failure</i> , 2014, 2, 289-297.	1.9	99
342	A Review of Quality-of-Life Evaluations in Patients with Congestive Heart Failure. <i>Pharmacoeconomics</i> , 1999, 16, 247-271.	1.7	97

#	ARTICLE	IF	CITATIONS
343	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013, 167, 1677-1687.	0.8	97
344	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 601-612.	1.2	97
345	Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. <i>PLoS Medicine</i> , 2018, 15, e1002541.	3.9	97
346	Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. <i>European Heart Journal</i> , 1999, 20, 1182-1190.	1.0	96
347	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006541.	1.6	96
348	Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. <i>European Heart Journal</i> , 2009, 30, 2226-2232.	1.0	95
349	Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 129-137.	2.9	95
350	Is the Pregnancy Hormone Relaxin Also a Vasodilator Peptide Secreted by the Heart?. <i>Circulation</i> , 2002, 106, 292-295.	1.6	94
351	The complex nature of informal care in home-based heart failure management. <i>Journal of Advanced Nursing</i> , 2008, 61, 373-383.	1.5	94
352	Outcomes and Effect of Treatment According to Etiology in HFrEF. <i>JACC: Heart Failure</i> , 2019, 7, 457-465.	1.9	94
353	Impaired endothelium-dependent vasodilatation in uraemia. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 1194-1200.	0.4	93
354	Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. <i>European Heart Journal</i> , 2012, 33, 314-324.	1.0	93
355	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	93
356	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 888-895.	2.9	93
357	Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. <i>New England Journal of Medicine</i> , 2015, 373, 2289-2290.	13.9	92
358	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation. <i>Circulation</i> , 2015, 131, 1486-1494.	1.6	92
359	Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 561-568.	1.6	91
360	Galectin-3 and Cardiac Function in Survivors of Acute Myocardial Infarction. <i>Circulation: Heart Failure</i> , 2013, 6, 492-498.	1.6	91

#	ARTICLE	IF	CITATIONS
361	Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 317-326.	1.9	91
362	Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 844-851.	2.9	91
363	Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 2147-2156.	2.9	91
364	Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. <i>European Heart Journal</i> , 2008, 29, 1739-1752.	1.0	90
365	Heart Failure After Acute Myocardial Infarction. <i>Circulation</i> , 2008, 118, 2019-2021.	1.6	90
366	Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms. <i>Circulation</i> , 2012, 126, 2317-2323.	1.6	90
367	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020, 41, 3402-3418.	1.0	90
368	Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbeopetin Alfa. <i>Circulation</i> , 2011, 124, 2903-2908.	1.6	89
369	Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	89
370	Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure. <i>Lancet, The</i> , 1998, 352, 201-202.	6.3	88
371	Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. <i>European Heart Journal</i> , 2007, 28, 326-333.	1.0	88
372	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	1.2	88
373	Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2016, 18, 328-336.	2.9	88
374	Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFrEF. <i>Journal of the American College of Cardiology</i> , 2020, 75, 245-254.	1.2	88
375	Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 882-894.	2.9	88
376	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2352-2361.	3.0	88
377	Effects of Urotensin II in Human Arteries and Veins of Varying Caliber. <i>Circulation</i> , 2001, 103, 1378-1381.	1.6	87
378	Ultrasound imaging of congestion in heart failure: examinations beyond the heart. <i>European Journal of Heart Failure</i> , 2021, 23, 703-712.	2.9	87

#	ARTICLE	IF	CITATIONS
379	Effect of Dapagliflozin in Patients With HFREF Treated With Sacubitril/Valsartan. JACC: Heart Failure, 2020, 8, 811-818.	1.9	87
380	Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes and Endocrinology, 2021, 9, 743-754.	5.5	87
381	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes and Endocrinology, 2021, 9, 755-766.	5.5	86
382	Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992. European Heart Journal, 1998, 19, 1829-1835.	1.0	85
383	New Therapeutic Options in Congestive Heart Failure. Circulation, 2002, 105, 2223-2228.	1.6	85
384	The prevalence and importance of frailty in heart failure with reduced ejection fraction - An analysis of PARADIGM-HF and ATMOSPHERE. European Journal of Heart Failure, 2020, 22, 2123-2133.	2.9	85
385	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation, 2021, 143, 438-448.	1.6	85
386	Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. American Heart Journal, 2008, 156, 623-632.	1.2	84
387	Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. European Journal of Heart Failure, 2009, 11, 684-690.	2.9	84
388	Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. European Journal of Heart Failure, 2010, 12, 17-24.	2.9	84
389	Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials?. European Heart Journal, 2012, 33, 2764-2765.	1.0	84
390	Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1845-1854.	1.2	84
391	Efficacy of Sacubitril/Valsartan Relative to Prior Decompensation. JACC: Heart Failure, 2016, 4, 816-822.	1.9	84
392	Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure. JAMA Cardiology, 2018, 3, 498.	3.0	84
393	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Therapy. Circulation: Heart Failure, 2016, 9, .	1.6	83
394	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2019, 21, 1199-1208.	2.2	83
395	BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 1149-1151.	1.8	83
396	Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart, 2010, 96, 533-538.	1.2	82

#	ARTICLE	IF	CITATIONS
397	Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). <i>American Journal of Nephrology</i> , 2013, 37, 212-222.	1.4	82
398	Selecting Patients for Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1944-1959.	1.2	81
399	Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. <i>BMJ Open</i> , 2014, 4, e005354-e005354.	0.8	81
400	Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 1236-1245.	1.6	81
401	Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. <i>European Journal of Heart Failure</i> , 2011, 13, 148-153.	2.9	80
402	The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>American Heart Journal</i> , 2012, 164, 878-883.	1.2	80
403	Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. <i>Circulation: Heart Failure</i> , 2014, 7, 953-959.	1.6	80
404	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (Iâ€œPreserve). <i>European Journal of Heart Failure</i> , 2014, 16, 778-787.	2.9	80
405	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , 2015, 36, 434-439.	1.0	80
406	Palliative care for heart failure. <i>BMJ: British Medical Journal</i> , 2002, 325, 915-916.	2.4	79
407	Extracellular Matrix Turnover and Inflammatory Markers Independently Predict Functional Status and Outcome in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, 467-474.	0.7	79
408	'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) <i>Tj ETQq0 0 Q rrgBT /Overlock 10 T</i>	1.6	79
409	Prevention & Rehabilitation (EACPR). [<i>Eur Heart J</i> 2012;33:1635-1701, doi: 10.1093/eurheartj/ehs092]. <i>European Heart Journal</i> , 2012, 33, 2126-2126. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2013, 34, 2823-2829.	1.0	79
410	Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials. <i>PLoS Medicine</i> , 2012, 9, e1001310.	3.9	78
411	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 3442-3451.	1.0	78
412	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006539.	1.6	78
413	Real-world studies no substitute for RCTs in establishing efficacy. <i>Lancet, The</i> , 2019, 393, 210-211.	6.3	78
414	Health-Related Quality of Life in Heartâ€œFailure With Preserved Ejectionâ€œFraction. <i>JACC: Heart Failure</i> , 2019, 7, 862-874.	1.9	77

#	ARTICLE	IF	CITATIONS
415	Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. <i>Journal of the American College of Cardiology</i> , 2020, 76, 503-514.	1.2	77
416	VALsartan In Acute myocardial infarcTion (VALIANT) trial: baseline characteristics in context. <i>European Journal of Heart Failure</i> , 2003, 5, 537-544.	2.9	76
417	EMPA-REG â€œ the â€œdiuretic hypothesisâ€œ. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 3-4.	1.2	76
418	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. <i>European Journal of Heart Failure</i> , 2013, 15, 947-959.	2.9	75
419	Effect of oral digoxin in highâ€risk heart failure patients: a preâ€specified subgroup analysis of the DIG trial. <i>European Journal of Heart Failure</i> , 2013, 15, 551-559.	2.9	75
420	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation</i> , 2015, 131, 43-53.	1.6	75
421	Role of Bâ€type Natriuretic Peptide and Nâ€terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	75
422	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the <scp>EMPHASISâ€HF</scp> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1186-1197.	2.9	75
423	Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. <i>European Heart Journal</i> , 2021, 42, 1216-1227.	1.0	75
424	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. <i>JACC: Heart Failure</i> , 2021, 9, 254-264.	1.9	75
425	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 184-197.	1.9	75
426	Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. <i>European Journal of Heart Failure</i> , 2007, 9, 110-112.	2.9	74
427	Traditional and new composite endpoints inâ€heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. <i>European Journal of Heart Failure</i> , 2016, 18, 482-489.	2.9	74
428	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2019, 140, 1369-1379.	1.6	74
429	Sacubitrilâ€valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3741-3752.	1.0	74
430	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2006, 152, 86-92.	1.2	74
431	An economic analysis of specialist heart failure nurse management in the U.K. Can we afford not to implement it?. <i>European Heart Journal</i> , 2002, 23, 1369-1378.	1.0	73
432	Which Inhibitor of the Reninâ€Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction?. <i>Circulation</i> , 2004, 110, 3281-3288.	1.6	73

#	ARTICLE	IF	CITATIONS
433	Plasma apelin concentration is depressed following acute myocardial infarction in man. <i>European Journal of Heart Failure</i> , 2009, 11, 551-558.	2.9	73
434	“Hearts and minds”: association, causation and implication of cognitive impairment in heart failure. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 22.	3.0	73
435	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , 2021, 78, 97-108.	1.2	73
436	The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1238-1245.	1.2	72
437	Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). <i>American Heart Journal</i> , 2011, 162, 748-755.e3.	1.2	72
438	Role of diuretics, A blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. <i>BMJ, The</i> , 2013, 347, f6745-f6745.	3.0	72
439	Statistical Controversies in Reporting of Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2648-2662.	1.2	72
440	The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 429-441.	1.9	72
441	Neurohumoral Pathways in Heart Failure With Preserved Systolic Function. <i>Progress in Cardiovascular Diseases</i> , 2005, 47, 357-366.	1.6	71
442	Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure. <i>European Heart Journal</i> , 2005, 26, 1759-1764.	1.0	71
443	Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. <i>European Journal of Heart Failure</i> , 2010, 12, 607-616.	2.9	71
444	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012, 14, 681-695.	2.9	71
445	Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). <i>European Heart Journal</i> , 2014, 35, 2714-2721.	1.0	71
446	Treatment of Heart Failure with Spironolactone “ Trial and Tribulations. <i>New England Journal of Medicine</i> , 2004, 351, 526-528.	13.9	70
447	Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 697-703.	5.5	70
448	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-III): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021, 23, 1040-1048.	2.9	70
449	Relation between socioeconomic deprivation and death from a first myocardial infarction in Scotland: population based analysis. <i>BMJ: British Medical Journal</i> , 2001, 322, 1152-1153.	2.4	69
450	Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. <i>Journal of Cardiac Failure</i> , 2004, 10, 155-164.	0.7	69

#	ARTICLE	IF	CITATIONS
451	Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. <i>Hypertension</i> , 2008, 51, 48-54.	1.3	69
452	Sex Differences in Incidence, Mortality, and Survival in Individuals With Stroke in Scotland, 1986 to 2005. <i>Stroke</i> , 2009, 40, 1038-1043.	1.0	69
453	Microvascular Obstruction Remains a Portent of Adverse Remodeling in Optimally Treated Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 360-367.	1.3	69
454	Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019, 8, e013114.	1.6	69
455	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2018, 3, 164.	3.0	68
456	Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). <i>American Heart Journal</i> , 2005, 150, 46-53.	1.2	67
457	Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function. <i>European Journal of Heart Failure</i> , 2007, 9, 865-871.	2.9	67
458	CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 929-936.	2.9	67
459	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. <i>European Journal of Heart Failure</i> , 2014, 16, 671-677.	2.9	67
460	Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1106-1113.	1.2	67
461	World Heart Federation Roadmap for Heart Failure. <i>Global Heart</i> , 2019, 14, 197.	0.9	67
462	Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1794.	3.8	66
463	The cost of acute myocardial infarction in the new millennium: Evidence from a multinational registry. <i>American Heart Journal</i> , 2006, 151, 206-212.	1.2	66
464	Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 1120-1127.	2.9	66
465	Rationale and design of the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF). <i>European Journal of Heart Failure</i> , 2010, 12, 617-622.	2.9	66
466	Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. <i>European Heart Journal</i> , 2012, 33, 1137-1141.	1.0	66
467	Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials. <i>Circulation</i> , 2018, 138, 570-577.	1.6	66
468	Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study. <i>Journal of Cardiac Failure</i> , 2015, 21, 179-188.	0.7	65

#	ARTICLE	IF	CITATIONS
469	Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. <i>European Journal of Heart Failure</i> , 2018, 20, 295-303.	2.9	65
470	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	1.0	65
471	A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1175-1182.	2.9	64
472	Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. <i>Clinical Research in Cardiology</i> , 2019, 108, 477-486.	1.5	64
473	Sacubitril/Valsartan. <i>JACC: Heart Failure</i> , 2020, 8, 800-810.	1.9	64
474	Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial. <i>Circulation: Heart Failure</i> , 2012, 5, 217-225.	1.6	63
475	Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. <i>European Journal of Heart Failure</i> , 2014, 16, 68-75.	2.9	63
476	Income Inequality and Outcomes in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 336-346.	1.9	63
477	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. <i>Circulation</i> , 2020, 142, 1205-1218.	1.6	63
478	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. <i>European Heart Journal</i> , 2015, 36, 669-675.	1.0	62
479	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , 2018, 20, 760-768.	2.9	62
480	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. <i>Circulation</i> , 2020, 141, 843-862.	1.6	62
481	Effect of Angiotensin-(1-7) and Bradykinin in Patients With Heart Failure Treated With an ACE Inhibitor. <i>Hypertension</i> , 1999, 34, 457-460.	1.3	61
482	Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. <i>Diabetes Care</i> , 2009, 32, 915-920.	4.3	61
483	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014, 35, 42-47.	1.0	61
484	Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. <i>Heart</i> , 2018, 104, 144-150.	1.2	61
485	Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2009, 54, 59-69.	2.1	60
486	Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1369-1376.	2.2	60

#	ARTICLE	IF	CITATIONS
487	Which patients with heart failure should receive specialist palliative care?. <i>European Journal of Heart Failure</i> , 2018, 20, 1338-1347.	2.9	60
488	Diabetic cardiomyopathy. <i>Heart</i> , 2019, 105, 337-345.	1.2	60
489	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. <i>European Journal of Heart Failure</i> , 2010, 12, 557-565.	2.9	59
490	Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). <i>European Journal of Heart Failure</i> , 2012, 14, 909-915.	2.9	59
491	The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*. <i>Journal of Internal Medicine</i> , 2012, 271, 436-443.	2.7	59
492	Prognostic Effect of High-Sensitive Troponin T Assessment in Elderly Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 96-103.	1.6	59
493	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 86-94.	1.4	59
494	Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. <i>European Journal of Heart Failure</i> , 2018, 20, 491-500.	2.9	59
495	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 432.	3.0	59
496	Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 898-901.	2.9	59
497	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 26.	3.0	59
498	"I don't like Mondays"--day of the week of coronary heart disease deaths in Scotland: study of routinely collected data. <i>BMJ: British Medical Journal</i> , 2000, 320, 218-219.	2.4	58
499	Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. <i>European Journal of Heart Failure</i> , 2001, 3, 495-502.	2.9	58
500	Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 870-880.	1.9	58
501	Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). <i>European Heart Journal</i> , 2017, 38, ehw387.	1.0	58
502	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	58
503	Changes in notions about heart failure. <i>Lancet, The</i> , 2001, 358, 432-434.	6.3	57
504	Discordant Short- and Long-Term Outcomes Associated With Diabetes in Patients With Heart Failure: Importance of Age and Sex. <i>Circulation: Heart Failure</i> , 2008, 1, 234-241.	1.6	57

#	ARTICLE	IF	CITATIONS
505	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326.	0.7	57
506	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , 2015, 170, 290-297.e1.	1.2	57
507	Making Sense of Statistics in Clinical Trial Reports. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2536-2549.	1.2	57
508	Effect of dapagliflozin on anaemia in <sc>DAPAâ€HF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 617-628.	2.9	57
509	Neurohormonal Activation in Acute Heart Failure: Results from VERITAS. <i>Cardiology</i> , 2011, 119, 96-105.	0.6	56
510	Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 387-393.	1.0	56
511	Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. <i>European Journal of Heart Failure</i> , 2016, 18, 1238-1243.	2.9	56
512	European Society of Cardiology - Acute Cardiovascular Care Association position paper on safe discharge of acute heart failure patients from the emergency department. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 311-320.	0.4	56
513	Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1701-1709.	2.9	56
514	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause. <i>JACC: Heart Failure</i> , 2020, 8, 844-855.	1.9	56
515	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. <i>Annals of Internal Medicine</i> , 2022, 175, 820-830.	2.0	56
516	How should we optimize cardiac resynchronization therapy?. <i>European Heart Journal</i> , 2008, 29, 2458-2472.	1.0	55
517	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 545-549.	1.3	55
518	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. <i>Circulation: Heart Failure</i> , 2018, 11, e004745.	1.6	55
519	Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1118-1127.	3.0	55
520	The struggle towards a Universal Definition of Heart Failure- how to proceed?. <i>European Heart Journal</i> , 2021, 42, 2331-2343.	1.0	55
521	The prevalence, nature, and importance of hematologic abnormalities in heart failure. <i>American Heart Journal</i> , 2006, 151, 1313-1321.	1.2	54
522	Left ventricular remodeling after acute myocardial infarction: Does eplerenone have an effect?. <i>American Heart Journal</i> , 2009, 157, 1088-1096.	1.2	54

#	ARTICLE	IF	CITATIONS
523	Digoxin Reduces 30-day All-cause Hospital Admission in Older Patients with Chronic Systolic Heart Failure. <i>American Journal of Medicine</i> , 2013, 126, 701-708.	0.6	54
524	The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 1491-1498.	2.9	54
525	Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the <sc>CHARM</sc> study programme. <i>European Journal of Heart Failure</i> , 2016, 18, 1508-1517.	2.9	54
526	The prognostic value of troponin T and N-terminal pro-B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. <i>European Journal of Heart Failure</i> , 2019, 21, 40-49.	2.9	54
527	Endothelin Receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction. <i>Journal of the American College of Cardiology</i> , 1999, 33, 932-938.	1.2	53
528	Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial. <i>Journal of Cardiac Failure</i> , 2010, 16, 128-134.	0.7	53
529	Darbepoetin Alfa Impact on Health Status in Diabetes Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 845-855.	2.2	53
530	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. <i>European Heart Journal</i> , 2015, 36, 1106-1114.	1.0	53
531	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	53
532	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	53
533	Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence. <i>Current Atherosclerosis Reports</i> , 2019, 21, 41.	2.0	53
534	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 372-381.	1.9	53
535	Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. <i>European Journal of Heart Failure</i> , 2020, 22, 1777-1785.	2.9	53
536	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. <i>Kidney International</i> , 2022, 101, 174-184.	2.6	53
537	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. <i>Circulation</i> , 2022, 146, 438-449.	1.6	53
538	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-PRESERVE study. <i>European Journal of Heart Failure</i> , 2015, 17, 809-817.	2.9	52
539	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	52
540	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 504-510.	2.9	52

#	ARTICLE	IF	CITATIONS
541	Heart Failure With Preserved Ejection Fraction in the Young. <i>Circulation</i> , 2018, 138, 2763-2773.	1.6	52
542	Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. <i>Diabetes Care</i> , 2019, 42, 1792-1799.	4.3	52
543	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 974-984.	2.9	52
544	Higher Body Mass Index in Adolescence Predicts Cardiomyopathy Risk in Midlife. <i>Circulation</i> , 2019, 140, 117-125.	1.6	52
545	The Pharmacoeconomics of ACE Inhibitors in Chronic Heart Failure. <i>Pharmacoeconomics</i> , 1996, 9, 188-197.	1.7	51
546	Mapping the emergence of heart disease in a black, urban population in Africa: The Heart of Soweto Study. <i>International Journal of Cardiology</i> , 2006, 108, 101-108.	0.8	51
547	A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. <i>American Heart Journal</i> , 2011, 161, 210-219.e1.	1.2	51
548	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitusâ€”Rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2018, 203, 30-38.	1.2	51
549	The Serendipitous Story of SGLT2 Inhibitors in Heart Failure. <i>Circulation</i> , 2019, 139, 2537-2541.	1.6	51
550	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, 1623-1632.	1.6	51
551	Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1818-1824.	15.2	51
552	Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. <i>European Journal of Heart Failure</i> , 2007, 9, 429-434.	2.9	50
553	Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial. <i>European Heart Journal</i> , 2007, 28, 685-691.	1.0	50
554	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. <i>American Heart Journal</i> , 2014, 168, 23-29.e2.	1.2	50
555	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (<sc>VALIANT</sc>). <i>European Journal of Heart Failure</i> , 2015, 17, 301-312.	2.9	50
556	Return to the Workforce After First Hospitalization for Heart Failure. <i>Circulation</i> , 2016, 134, 999-1009.	1.6	50
557	Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. <i>Heart</i> , 2018, 104, 1006-1013.	1.2	50
558	Randomized Trials Versus Common Sense and Clinical Observation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 580-589.	1.2	50

#	ARTICLE	IF	CITATIONS
559	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , 2021, 44, 586-594.	4.3	50
560	Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. <i>Heart Rhythm</i> , 2006, 3, 313-316.	0.3	49
561	Is a reduction in albuminuria associated with renal and cardiovascular protection? A <i>post hoc</i> analysis of the <i>ALTITUDE</i> trial. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 169-177.	2.2	49
562	How robust are clinical trials in heart failure?. <i>European Heart Journal</i> , 2017, 38, ehw427.	1.0	49
563	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 807-820.	1.9	49
564	Red cell distribution width has incremental prognostic value to B-type natriuretic peptide in acute heart failure. <i>European Journal of Heart Failure</i> , 2009, 11, 1152-1154.	2.9	48
565	Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. <i>American Heart Journal</i> , 2009, 157, 957-970.	1.2	48
566	How Small Is Too Small? A Systematic Review of Center Volume and Outcome After Cardiac Transplantation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 783-790.	0.9	48
567	Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review. <i>European Journal of Heart Failure</i> , 2015, 17, 906-916.	2.9	48
568	Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the <i>MAGGIC</i> meta-analysis. <i>European Journal of Heart Failure</i> , 2015, 17, 1182-1191.	2.9	48
569	Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The <i>Heart OMics</i> ™ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. <i>BMC Medicine</i> , 2016, 14, 181.	2.3	48
570	Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1647-1656.	0.4	48
571	Effects of a Xanthine Oxidase/Hypoxanthine Free Radical and Reactive Oxygen Species Generating System on Endothelial Function in New Zealand White Rabbit Aortic Rings. <i>Journal of Cardiovascular Pharmacology</i> , 1993, 22, 792-797.	0.8	47
572	Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction. <i>Current Heart Failure Reports</i> , 2006, 3, 175-180.	1.3	47
573	Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme. <i>European Journal of Heart Failure</i> , 2007, 9, 510-517.	2.9	47
574	Corrigendum to "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008" [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. <i>European Heart Journal</i> , 2008, 29, 3069-3069.	1.0	47
575	Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial infarction trial (VALIANT). <i>European Heart Journal</i> , 2009, 30, 1450-1456.	1.0	47
576	Lessons from the TOPCAT Trial. <i>New England Journal of Medicine</i> , 2014, 370, 1453-1454.	13.9	47

#	ARTICLE	IF	CITATIONS
577	Predicting heart failure decompensation using cardiac implantable electronic devices: a review of practices and challenges. <i>European Journal of Heart Failure</i> , 2016, 18, 977-986.	2.9	47
578	Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. <i>European Journal of Heart Failure</i> , 2016, 18, 290-297.	2.9	47
579	Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2101.	3.8	47
580	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: ^{GALACTIC} baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	2.9	47
581	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. <i>Diabetes Care</i> , 2021, 44, 1894-1897.	4.3	47
582	Role of Bradykinin in the Vasodilator Effects of Losartan and Enalapril in Patients With Heart Failure. <i>Circulation</i> , 1999, 100, 268-273.	1.6	46
583	Treatment of chronic heart failure: a comparison between the major guidelines. <i>European Heart Journal</i> , 2006, 27, 1773-1777.	1.0	46
584	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1644-1656.	1.2	46
585	The interrelationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. <i>European Journal of Heart Failure</i> , 2010, 12, 1229-1237.	2.9	45
586	Liver function tests in patients with acute heart failure and associated outcomes: insights from ^{ASCEND-HF}. <i>European Journal of Heart Failure</i> , 2016, 18, 424-432.	2.9	45
587	Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 68-77.	1.9	45
588	Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1139-1145.	2.9	45
589	Electrical cardioversion for atrial fibrillation: outcomes in "real-life" clinical practice. <i>International Journal of Cardiology</i> , 2001, 81, 29-35.	0.8	44
590	Vasoconstrictor Effect of the Angiotensin-Converting Enzyme-Resistant, Chymase-Specific Substrate [Pro ¹¹ D ₁₂ -Ala ¹²] Angiotensin I in Human Dorsal Hand Veins. <i>Circulation</i> , 2001, 104, 1805-1808.	1.6	44
591	Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. <i>European Heart Journal</i> , 2010, 31, 211-221.	1.0	44
592	Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. <i>International Journal of Cardiology</i> , 2013, 168, 1094-1101.	0.8	44
593	Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. <i>Lancet, The</i> , 2017, 389, 1831-1840.	6.3	44
594	Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1717-1727.	1.2	44

#	ARTICLE	IF	CITATIONS
595	Effect of candesartan on New York Heart Association functional classResults of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 2004, 25, 1920-1926.	1.0	43
596	Neprilysin Inhibition for Heart Failure. New England Journal of Medicine, 2014, 371, 2335-2337.	13.9	43
597	Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction. Circulation: Heart Failure, 2014, 7, 895-902.	1.6	43
598	The Emerging Potential of the Apelin-APJ System in Heart Failure. Journal of Cardiac Failure, 2015, 21, 489-498.	0.7	43
599	B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulmonary Medicine, 2017, 17, 11.	0.8	43
600	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. JACC: Heart Failure, 2018, 6, 564-569.	1.9	43
601	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. European Journal of Heart Failure, 2019, 21, 345-351.	2.9	43
602	Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. Journal of the American College of Cardiology, 2008, 52, 2000-2007.	1.2	42
603	Soluble Glycoprotein 130 Predicts Fatal Outcomes in Chronic Heart Failure. Circulation: Heart Failure, 2013, 6, 91-98.	1.6	42
604	Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. Circulation: Heart Failure, 2014, 7, 918-925.	1.6	42
605	Practical approach on frail older patients attended for acute heart failure. International Journal of Cardiology, 2016, 222, 62-71.	0.8	42
606	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. European Journal of Heart Failure, 2018, 20, 268-277.	2.9	42
607	Association is not causation: treatment effects cannot be estimated from observational data in heart failure. European Heart Journal, 2018, 39, 3417-3438.	1.0	42
608	Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. European Journal of Heart Failure, 1999, 1, 67-72.	2.9	41
609	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. Circulation, 2014, 130, 958-965.	1.6	41
610	Improving outcomes in heart failure: a personal perspective. European Heart Journal, 2015, 36, 3467-3470.	1.0	41
611	European Society of Cardiology-Acute Cardiovascular Care Association Position paper on acute heart failure: A call for interdisciplinary care. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 81-86.	0.4	41
612	The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. American Heart Journal, 2017, 187, 145-155.	1.2	41

#	ARTICLE	IF	CITATIONS
613	Accelerated and personalized therapy for heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2022, 43, 2573-2587.	1.0	41
614	Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure–Assessment of Reduction in Mortality and morbidity programme. <i>European Heart Journal</i> , 2008, 29, 3022-3028.	1.0	40
615	Fatigue as a Predictor of Outcome in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 187-197.	1.9	40
616	Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. <i>European Heart Journal</i> , 2016, 37, 466-472.	1.0	40
617	IGFBP7 (Insulin-Like Growth Factor–Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e005133.	1.6	40
618	Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 165-178.	1.4	40
619	Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. <i>Circulation</i> , 2021, 144, 199-209.	1.6	40
620	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 24-34.	5.5	40
621	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <i>Revista Española De Cardiología</i> , 2022, 75, 523.e1-523.e114.	0.6	40
622	Even low-dose aspirin inhibits arachidonic acid–induced vasodilation in heart failure. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 530-537.	2.3	39
623	Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. <i>American Heart Journal</i> , 2011, 162, 685-691.	1.2	39
624	Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. <i>European Journal of Heart Failure</i> , 2011, 13, 1305-1313.	2.9	39
625	Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. <i>European Journal of Heart Failure</i> , 2015, 17, 434-441.	2.9	39
626	Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 309-317.	5.5	39
627	Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2893-2904.	1.2	39
628	How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 506-522.	1.1	39
629	Endothelin receptor antagonism in patients with chronic heart failure. <i>Cardiovascular Research</i> , 2000, 47, 166-172.	1.8	38
630	Failing ageing hearts. <i>European Heart Journal</i> , 2001, 22, 1978-1990.	1.0	38

#	ARTICLE	IF	CITATIONS
631	Trends in case-fatality in 22 968 patients admitted for the first time with atrial fibrillation in Scotland, 1986-1995. <i>International Journal of Cardiology</i> , 2002, 82, 229-236.	0.8	38
632	How much responsibility should heart failure nurses take?. <i>European Journal of Heart Failure</i> , 2005, 7, 351-361.	2.9	38
633	Determining the most appropriate components for a composite clinical trial outcome. <i>American Heart Journal</i> , 2008, 156, 633-640.	1.2	38
634	Clinical development of pharmacologic agents for acute heart failure syndromes: A proposal for a mechanistic translational phase. <i>American Heart Journal</i> , 2011, 161, 224-232.	1.2	38
635	Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. <i>European Journal of Heart Failure</i> , 2012, 14, 185-192.	2.9	38
636	Effects of Neutral Endopeptidase (Nepriylsin) Inhibition on the Response to Other Vasoactive Peptides in Small Human Resistance Arteries: Studies with Thiorphan and Omapatrilat. <i>Cardiovascular Therapeutics</i> , 2014, 32, 13-18.	1.1	38
637	Thyroid-Stimulating Hormone and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2014, 2, 35-40.	1.9	38
638	Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. <i>Diabetes Care</i> , 2018, 41, 1285-1291.	4.3	38
639	Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Nepriylsin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 1226.	3.0	38
640	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , 2019, 21, 577-587.	2.9	38
641	Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 188-198.	1.9	38
642	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. <i>European Heart Journal</i> , 2020, 41, 2356-2362.	1.0	38
643	Heart failure: we need more trials in typical patients. <i>European Heart Journal</i> , 2000, 21, 699-700.	1.0	37
644	Effect of socioeconomic deprivation on the population risk of incident heart failure hospitalisation: An analysis of the Renfrew/Paisley Study. <i>European Journal of Heart Failure</i> , 2006, 8, 856-863.	2.9	37
645	ACE Inhibitors in Cardiovascular Disease - Unbeatable?. <i>New England Journal of Medicine</i> , 2008, 358, 1615-1616.	13.9	37
646	Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1301-1305.	0.9	37
647	Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 554-561.	1.5	37
648	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. <i>Clinical Chemistry</i> , 2015, 61, 368-378.	1.5	37

#	ARTICLE	IF	CITATIONS
649	Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	37
650	Urinary peptides in heart failure: a link to molecular pathophysiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1875-1887.	2.9	37
651	A1 H spin echo and 51V NMR study of the interaction of vanadate with intact erythrocytes. <i>Journal of Biological Inorganic Chemistry</i> , 1997, 2, 235-241.	1.1	36
652	ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: Hemodynamic and neurohormonal effects. <i>American Heart Journal</i> , 2001, 141, 800-807.	1.2	36
653	Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. <i>European Journal of Heart Failure</i> , 2010, 12, 936-942.	2.9	36
654	Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials. <i>JACC: Heart Failure</i> , 2015, 3, 603-614.	1.9	36
655	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 169-176.	2.9	36
656	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 306-313.	2.9	36
657	The ICD in Heart Failure – Time for a Rethink?. <i>New England Journal of Medicine</i> , 2016, 375, 1283-1284.	13.9	36
658	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017, 38, ehw509.	1.0	36
659	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 834-844.	2.9	36
660	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , 2021, 23, 1662-1672.	2.9	36
661	The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. <i>Kidney International Reports</i> , 2022, 7, 436-443.	0.4	36
662	Reduced costs with bisoprolol treatment for heart failure; an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). <i>European Heart Journal</i> , 2001, 22, 1021-1031.	1.0	35
663	Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2005, 27, 1447-1458.	1.0	35
664	Assessment of Dyspnea in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1441-1448.	1.2	35
665	Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. <i>American Heart Journal</i> , 2013, 166, 935-940.e1.	1.2	35
666	Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy. <i>Circulation: Heart Failure</i> , 2013, 6, 711-718.	1.6	35

#	ARTICLE	IF	CITATIONS
667	History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 960-966.	1.6	35
668	Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015, 17, 1201-1207.	2.9	35
669	Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function. <i>JACC: Heart Failure</i> , 2015, 3, 40-49.	1.9	35
670	Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2016, 134, 1785-1787.	1.6	35
671	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 20-28.	0.7	35
672	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 514-522.	2.9	35
673	Conduct of Clinical Trials in the Era of COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2368-2378.	1.2	35
674	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1961-1973.	1.2	35
675	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021, 143, 1962-1972.	1.6	35
676	Free radical scavenging: a potentially beneficial action of thiol-containing angiotensin converting enzyme inhibitors. <i>Biochemical Society Transactions</i> , 1990, 18, 1184-1185.	1.6	34
677	Seasonal variation in morbidity and mortality related to atrial fibrillation. <i>International Journal of Cardiology</i> , 2004, 97, 283-288.	0.8	34
678	Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction†. <i>European Journal of Heart Failure</i> , 2006, 8, 577-584.	2.9	34
679	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 792-799.	2.9	34
680	NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e017462.	1.6	34
681	Serum potassium in the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2056-2064.	2.9	34
682	Use of the Win Ratio in Cardiovascular Trials. <i>JACC: Heart Failure</i> , 2020, 8, 441-450.	1.9	34
683	Signalling mechanisms underlying the myogenic response in human subcutaneous resistance arteries. <i>Cardiovascular Research</i> , 2001, 49, 828-837.	1.8	33
684	Patients strategies for managing medication for chronic heart failure. <i>International Journal of Cardiology</i> , 2006, 109, 66-73.	0.8	33

#	ARTICLE	IF	CITATIONS
685	Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. <i>American Heart Journal</i> , 2008, 155, 87-93.	1.2	33
686	A randomised trial of a pre-synaptic stimulator of DA ₂ dopaminergic and α_2 adrenergic receptors on morbidity and mortality in patients with heart failure. <i>European Journal of Heart Failure</i> , 2008, 10, 89-95.	2.9	33
687	Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). <i>American Heart Journal</i> , 2010, 160, 145-151.	1.2	33
688	Comorbidities and Differential Diagnosis in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2014, 10, 481-501.	1.0	33
689	Meta-Analysis of Large-Scale Randomized Trials to Determine the Effectiveness of Inhibition of the Renin-Angiotensin Aldosterone System in Heart Failure. <i>American Journal of Cardiology</i> , 2015, 116, 155-161.	0.7	33
690	MRAs in Elderly HF Patients. <i>JACC: Heart Failure</i> , 2019, 7, 1012-1021.	1.9	33
691	Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: <sc>PARAGONâ€HF</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 2093-2101.	2.9	33
692	Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1662-1671.	2.9	33
693	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the <sc>DAPAâ€HF</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 601-613.	2.9	33
694	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <sc>DAPAâ€HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 513-525.	2.9	33
695	Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. <i>American Heart Journal</i> , 1993, 126, 879-886.	1.2	32
696	Effects of Chronic Norepinephrine Administration on Cardiac Function in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 26, 584-589.	0.8	32
697	Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1234-1238.	1.2	32
698	Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitus. <i>American Heart Journal</i> , 2015, 170, 322-329.e4.	1.2	32
699	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , 2017, 188, 35-41.	1.2	32
700	Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000523.	1.2	32
701	Diagnostic tests, drug prescriptions, and follow-up patterns after incident heart failure: A cohort study of 93,000 UK patients. <i>PLoS Medicine</i> , 2019, 16, e1002805.	3.9	32
702	Adrenomedullin selectively inhibits angiotensin II-induced aldosterone secretion in humans. <i>Journal of Hypertension</i> , 2000, 18, 61-64.	0.3	31

#	ARTICLE	IF	CITATIONS
703	Substantial between-hospital variation in outcome following first emergency admission for heart failure. <i>European Heart Journal</i> , 2002, 23, 650-657.	1.0	31
704	Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. <i>Heart</i> , 2010, 96, 838-842.	1.2	31
705	Mechanisms and Predictors of Mitral Regurgitation after High-Risk Myocardial Infarction. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 535-542.	1.2	31
706	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 938.e1-938.e59.	0.6	31
707	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000011.	1.2	31
708	The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from <sc>CIBIS</sc> and <sc>MERIT</sc> compared with stratified subsets from <sc>MERIT</sc> and <sc>HF</sc>. <i>Journal of Internal Medicine</i> , 2014, 275, 134-143.	2.7	31
709	Sacubitril/Valsartan (LCZ696) in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 133-165.	0.9	31
710	Rationale for and design of the <sc>TRUE&AHF</sc> trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 673-681.	2.9	31
711	Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. <i>European Heart Journal</i> , 2020, 41, 2353-2355.	1.0	31
712	The acute vascular effects of frusemide in heart failure. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 9-13.	1.1	30
713	Anemia and heart failure. <i>Current Heart Failure Reports</i> , 2004, 1, 176-182.	1.3	30
714	The treatment of heart failure with preserved ejection fraction (diastolic heart failure). <i>Heart Failure Reviews</i> , 2006, 11, 141-146.	1.7	30
715	Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Added trial. <i>European Journal of Heart Failure</i> , 2008, 10, 157-163.	2.9	30
716	Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011, 13, 746-754.	2.9	30
717	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2015, 36, 2310-2317.	1.0	30
718	Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 256-264.	1.9	30
719	Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. <i>American Journal of Nephrology</i> , 2018, 48, 260-268.	1.4	30
720	Diabetes and prediabetes in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 497-509.	2.9	30

#	ARTICLE	IF	CITATIONS
721	Increasing the impact of cardiological treatments. How best to reduce deaths. <i>European Heart Journal</i> , 1999, 20, 1386-1392.	1.0	29
722	High-risk myocardial infarction in the young: The VALsartan In Acute myocardial infarcTion (VALIANT) trial. <i>American Heart Journal</i> , 2008, 155, 706-711.	1.2	29
723	Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. <i>BMC Medicine</i> , 2010, 8, 23.	2.3	29
724	Cause of Death in Patients With Diabetic CKD Enrolled in theÂTrial to Reduce Cardiovascular Events With Aranesp TherapyÂ(TREAT). <i>American Journal of Kidney Diseases</i> , 2015, 66, 429-440.	2.1	29
725	Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. <i>European Heart Journal</i> , 2015, 36, 2463-2469.	1.0	29
726	Efficacy and safety of sodiumâ€“glucose coâ€“transporter 2 inhibition according to left ventricular ejection fraction in DAPAâ€“HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1247-1258.	2.9	29
727	β ₁ -Adrenoreceptor Autoantibodies in Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006155.	1.6	29
728	Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. <i>European Heart Journal</i> , 2005, 26, 2114-2119.	1.0	28
729	Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes. <i>Diabetes Care</i> , 2011, 34, 1394-1396.	4.3	28
730	Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC metaâ€“analysis report. <i>European Journal of Heart Failure</i> , 2013, 15, 1220-1227.	2.9	28
731	Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the <sc>VERITAS</sc> study. <i>European Journal of Heart Failure</i> , 2014, 16, 1362-1371.	2.9	28
732	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2016, 68, 873-881.	2.1	28
733	Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 377-382.	0.2	28
734	Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failureâ€“does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (<sc>VERITAS</sc>). <i>European Journal of Heart Failure</i> , 2017, 19, 739-747.	2.9	28
735	Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1472-1477.	0.8	28
736	Baseline characteristics and enrichment results from the <sc>SONAR</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1829-1835.	2.2	28
737	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 727-735.	1.2	28
738	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 528-538.	2.9	28

#	ARTICLE	IF	CITATIONS
739	Endpoints in Heart Failure Drug Development. <i>JACC: Heart Failure</i> , 2020, 8, 429-440.	1.9	28
740	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2022, 145, 87-89.	1.6	28
741	Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 1066-1076.	2.9	28
742	Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients. <i>JAMA Internal Medicine</i> , 2022, 182, 592.	2.6	28
743	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. <i>Diabetologia</i> , 2022, 65, 1085-1097.	2.9	28
744	Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. <i>American Journal of Medicine</i> , 2000, 109, 489-492.	0.6	27
745	Making sense of SENIORS. <i>European Heart Journal</i> , 2005, 26, 203-206.	1.0	27
746	Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. <i>Journal of Cardiac Failure</i> , 2016, 22, 815-822.	0.7	27
747	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1601-1610.	2.9	27
748	Clinical Trials Update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 459-465.	1.3	26
749	Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. <i>European Heart Journal</i> , 2008, 30, 338-345.	1.0	26
750	Age- and Sex-Specific Trends in Fatal Incidence and Hospitalized Incidence of Stroke in Scotland, 1986 to 2005. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 475-483.	0.9	26
751	Predictors of Incident Heart Failure Hospitalizations Among Patients With Impaired Glucose Tolerance. <i>Circulation: Heart Failure</i> , 2013, 6, 203-210.	1.6	26
752	Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. <i>Heart</i> , 2014, 100, 1681-1687.	1.2	26
753	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. <i>European Journal of Heart Failure</i> , 2016, 18, 1162-1171.	2.9	26
754	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) <small>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 0.7</small>	0.7	26
755	Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-9.	1.0	26
756	Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. <i>Circulation: Heart Failure</i> , 2018, 11, e004926.	1.6	26

#	ARTICLE	IF	CITATIONS
757	Risk stratification scores for patients with acute heart failure in the Emergency Department: A systematic review. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 375-398.	0.4	26
758	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2021, 77, 546-556.	1.3	26
759	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 678.	3.0	26
760	Head-to-head comparison of contemporary heart failure risk scores. <i>European Journal of Heart Failure</i> , 2021, 23, 2035-2044.	2.9	26
761	Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 377-386.	2.9	25
762	Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e002092.	1.6	25
763	Global Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e007901.	1.6	25
764	Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. <i>Diabetes Care</i> , 2021, 44, 1877-1884.	4.3	25
765	Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , 2005, 7, 650-656.	2.9	24
766	Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>American Heart Journal</i> , 2006, 152, 183-189.	1.2	24
767	Is Microvolt T-Wave Alternans the Answer to Risk Stratification in Heart Failure?. <i>Circulation</i> , 2007, 116, 2984-2991.	1.6	24
768	Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). <i>European Journal of Heart Failure</i> , 2010, 12, 698-705.	2.9	24
769	Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986 - 2005: a retrospective cohort study. <i>BMC Neurology</i> , 2011, 11, 38.	0.8	24
770	Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.	2.9	24
771	Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	24
772	Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. <i>Heart</i> , 2019, 105, 1325-1334.	1.2	24
773	The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. <i>European Heart Journal</i> , 2021, 42, 1199-1202.	1.0	24
774	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of <sc>DAPA-HF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 632-643.	2.9	24

#	ARTICLE	IF	CITATIONS
775	The assessment of the HO ¹ scavenging action of therapeutic agents. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1994, 12, 863-866.	1.4	23
776	Attenuation of endothelin-1 induced vasoconstriction by 17 β estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1367-1373.	1.2	23
777	Altered diaphragm position and function in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2001, 3, 183-187.	2.9	23
778	Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>American Heart Journal</i> , 2005, 150, 323-329.	1.2	23
779	Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. <i>BMJ Open</i> , 2012, 2, e001925.	0.8	23
780	When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches. <i>Circulation: Heart Failure</i> , 2012, 5, 294-302.	1.6	23
781	Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct. <i>American Heart Journal</i> , 2013, 166, 208-216.e28.	1.2	23
782	Large streamlined trials in cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 544-548.	1.0	23
783	Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2018, 20, 323-331.	2.9	23
784	Income level and inequality as complement to geographical differences in cardiovascular trials. <i>American Heart Journal</i> , 2019, 218, 66-74.	1.2	23
785	Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 374-382.	1.9	23
786	The effect of atrial natriuretic factor on urinary albumin and ??; 2-microglobulin excretion in man. <i>Journal of Hypertension</i> , 1988, 6, 783-786.	0.3	22
787	An Economic Analysis of the Survival and Ventricular Enlargement (SAVE) Study. <i>Pharmacoeconomics</i> , 1997, 12, 182-192.	1.7	22
788	Using Measures of Disease Progression to Determine Therapeutic Effect. <i>Journal of the American College of Cardiology</i> , 2006, 48, 434-437.	1.2	22
789	Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2008, 101, 925-929.	0.7	22
790	The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. <i>Life Sciences</i> , 2012, 91, 743-748.	2.0	22
791	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from <sc>ASCEND-HF</sc>. <i>European Journal of Heart Failure</i> , 2015, 17, 340-346.	2.9	22
792	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina. <i>Circulation: Heart Failure</i> , 2015, 8, 717-724.	1.6	22

#	ARTICLE	IF	CITATIONS
793	Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. <i>International Journal of Cardiology</i> , 2016, 209, 310-316.	0.8	22
794	Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 241-249.	2.9	22
795	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5). <i>Journal of the American College of Cardiology</i> , 2019, 74, 683-698.	1.2	22
796	Editor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 231-241.	0.4	22
797	Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. <i>JACC: Heart Failure</i> , 2021, 9, 13-24.	1.9	22
798	What are the clinical consequences of anemia in patients with chronic heart failure?. <i>Journal of Cardiac Failure</i> , 2004, 10, S10-S12.	0.7	21
799	Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. <i>Heart Rhythm</i> , 2007, 4, 308-313.	0.3	21
800	Approaches to the treatment of anaemia in patients with chronic heart failure. <i>Heart Failure Reviews</i> , 2008, 13, 431-438.	1.7	21
801	Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial) Diseases, 2013, 61, 238-246.	2.1	21
802	Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal events (BEACON) trial. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2841-2850.	0.4	21
803	Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design. <i>ESC Heart Failure</i> , 2015, 2, 25-36.	1.4	21
804	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 478-486.	1.9	21
805	Lessons in Uncertainty and Humility â€” Clinical Trials Involving Hypertension. <i>New England Journal of Medicine</i> , 2016, 375, 1756-1766.	13.9	21
806	Referral for Specialist Follow-up and Its Association With Post-discharge Mortality Among Patients With Systolic Heart Failure (from the National Heart Failure Audit for England and Wales). <i>American Journal of Cardiology</i> , 2017, 119, 440-444.	0.7	21
807	Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1248-1258.	2.9	21
808	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. <i>Circulation: Heart Failure</i> , 2019, 12, e005766.	1.6	21
809	Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. <i>American Heart Journal</i> , 2020, 222, 157-165.	1.2	21
810	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020, 43, 1077-1084.	4.3	21

#	ARTICLE	IF	CITATIONS
811	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in AHFpEF. <i>JACC: Heart Failure</i> , 2021, 9, 627-635.	1.9	21
812	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008837.	1.6	21
813	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2022, 79, 504-510.	1.2	21
814	Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the <sc>EMPEROR</sc> Preserved trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1869-1878.	2.9	21
815	Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction. <i>Cardiovascular Research</i> , 1998, 39, 563-570.	1.8	20
816	Prognostic impact of pulmonary arterial hypertension: A population-based analysis. <i>International Journal of Cardiology</i> , 2008, 124, 183-187.	0.8	20
817	Biomarkers in heart failure: a clinical review. <i>Heart Failure Reviews</i> , 2010, 15, 251-273.	1.7	20
818	Associations of chronic heart failure with outcome in acute ischaemic stroke patients who received systemic thrombolysis: analysis from VISTA. <i>European Journal of Neurology</i> , 2015, 22, 163-169.	1.7	20
819	Barcelona BioHF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization. <i>European Journal of Heart Failure</i> , 2018, 20, 938-940.	2.9	20
820	Systolic blood pressure reduction during the first 24h in acute heart failure admission: friend or foe?. <i>European Journal of Heart Failure</i> , 2018, 20, 317-322.	2.9	20
821	Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1022-1031.	2.9	20
822	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 418-427.	1.9	20
823	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. <i>Diabetes Care</i> , 2020, 43, 2878-2881.	4.3	20
824	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. <i>Journal of the American Heart Association</i> , 2021, 10, e019238.	1.6	20
825	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the <sc>PARADIGM-HF</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1518-1524.	2.9	20
826	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in <sc>PARADIGM-HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 551-561.	2.9	20
827	Calcium-antagonist controversy: the long and short of it?. <i>Lancet, The</i> , 1997, 349, 585-586.	6.3	19
828	Monocyte chemoattractant protein-1: A dichotomous role in cardiac remodeling following acute myocardial infarction in man?. <i>Cytokine</i> , 2010, 50, 158-162.	1.4	19

#	ARTICLE	IF	CITATIONS
829	Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011, 13, 755-764.	2.9	19
830	Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?. <i>European Heart Journal</i> , 2012, 33, 1049-1057.	1.0	19
831	Angina and intermittent claudication in 7403 participants of the 2003 Scottish Health Survey: Impact on general and mental health, quality of life and five-year mortality. <i>International Journal of Cardiology</i> , 2013, 167, 2149-2155.	0.8	19
832	The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27% patients. <i>European Journal of Heart Failure</i> , 2014, 16, 289-299.	2.9	19
833	Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>PLoS ONE</i> , 2015, 10, e0133970.	1.1	19
834	Telomere length and outcomes in ischaemic heart failure: data from the Controlled Rosuvastatin multinational Trial in Heart Failure (CORONA). <i>European Journal of Heart Failure</i> , 2015, 17, 313-319.	2.9	19
835	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 777-785.	1.9	19
836	Mind the Gap: Current Challenges and Future State of Heart Failure Care. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1434-1449.	0.8	19
837	Real World Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 315-322.	1.3	19
838	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2020, 22, 1402-1411.	2.9	19
839	Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. <i>JAMA Cardiology</i> , 2021, 6, 1415.	3.0	19
840	Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008597.	1.6	19
841	Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. <i>Journal of Cardiac Failure</i> , 2022, 28, 1050-1062.	0.7	19
842	Synergism of histidyl dipeptides as antioxidants. <i>Journal of Molecular and Cellular Cardiology</i> , 1991, 23, 1205-1207.	0.9	18
843	Clinical experience with endothelin receptor antagonists in chronic heart failure. <i>Heart Failure Reviews</i> , 2001, 6, 317-323.	1.7	18
844	Digitalis for treatment of heart failure in patients in sinus rhythm. , 2004, , CD002901.		18
845	Renin angiotensin blockade in heart failure with preserved ejection fraction: the signal gets stronger. <i>European Heart Journal</i> , 2006, 27, 2257-2259.	1.0	18
846	Transthoracic echocardiography: a survey of current practice in the UK. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 101, 345-349.	0.2	18

#	ARTICLE	IF	CITATIONS
847	Circumstances and Outcomes of Sudden Unexpected Death in Patients With High-Risk Myocardial Infarction. <i>Circulation</i> , 2011, 123, 2674-2680.	1.6	18
848	Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>European Heart Journal</i> , 2014, 35, 3426-3433.	1.0	18
849	The Aliskiren Trial to Minimize <scp>OutcomeS</scp> in Patients with <scp>HEart</scp> failure trial (<scp>ATMOSPHERE</scp>): revised statistical analysis plan and baseline characteristics. <i>European Journal of Heart Failure</i> , 2015, 17, 1075-1083.	2.9	18
850	Combined Free Light Chains Are Novel Predictors of Prognosis in Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 618-625.	1.9	18
851	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective. <i>JAMA Cardiology</i> , 2017, 2, 525.	3.0	18
852	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the <scp>ATMOSPHERE</scp> trial. <i>European Journal of Heart Failure</i> , 2018, 20, 136-147.	2.9	18
853	Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction. <i>Korean Circulation Journal</i> , 2019, 49, 469.	0.7	18
854	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019, 73, 309-315.	2.1	18
855	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2022, 145, 158-169.	1.6	18
856	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 336-346.	1.9	18
857	Development and validation of a decision support tool for the diagnosis of acute heart failure: systematic review, meta-analysis, and modelling study. <i>BMJ</i> , The, 0, , e068424.	3.0	18
858	Consequences of fluid loss in patients treated with ACE inhibitors.. <i>Postgraduate Medical Journal</i> , 1987, 63, 385-387.	0.9	17
859	Circulating Endothelin Is Not Extracted by the Pulmonary Circulation in Man. <i>Chest</i> , 1992, 102, 1143-1144.	0.4	17
860	A Qualitative Study of the Contribution of Pharmacists to Heart Failure Management in Scotland. <i>International Journal of Clinical Pharmacy</i> , 2005, 27, 453-458.	1.4	17
861	Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. <i>American Heart Journal</i> , 2011, 161, 1156-1162.	1.2	17
862	Plasma TIMP-4 Predicts Left Ventricular Remodeling After Acute Myocardial Infarction. <i>Journal of Cardiac Failure</i> , 2011, 17, 465-471.	0.7	17
863	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (â€PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1021-1031.	2.9	17
864	Clinical Trials Series. <i>New England Journal of Medicine</i> , 2016, 374, 2167-2167.	13.9	17

#	ARTICLE	IF	CITATIONS
865	Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. <i>Heart</i> , 2017, 103, 55-62.	1.2	17
866	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017, 19, 718-727.	2.9	17
867	Heart Failure. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 117-135.	1.2	17
868	Microvascular complications in diabetes patients with heart failure and reduced ejection fraction—insights from the Beta-blocker Evaluation of Survival Trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1549-1556.	2.9	17
869	Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. <i>Clinical Research in Cardiology</i> , 2019, 108, 1215-1225.	1.5	17
870	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 618-626.	1.9	17
871	Body mass index and changes on lung ultrasonography in chronic and acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 1201-1209.	1.4	17
872	Effects of a Novel Nitroxyl Donor in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 146-157.	1.9	17
873	Estimating the Benefits of Combination Medical Therapy in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. <i>Circulation</i> , 2022, 145, 1741-1743.	1.6	17
874	Alteration of the erythrocyte glutathione redox balance by N-acetylcysteine, captopril and exogenous glutathione. <i>FEBS Letters</i> , 1994, 347, 215-220.	1.3	16
875	Analysis of reproducibility of reference lumen quantitation with intravascular ultrasound in stented coronary arteries. <i>Catheterization and Cardiovascular Diagnosis</i> , 1997, 40, 1-7.		16
876	Are angiotensin ii receptor blockers more efficacious than placebo in heart failure? implications of elite-2. <i>American Journal of Cardiology</i> , 2001, 87, 606-607.	0.7	16
877	Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1865-1871.	1.2	16
878	An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. <i>European Journal of Heart Failure</i> , 2010, 12, 66-74.	2.9	16
879	B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway?. <i>Diabetologia</i> , 2012, 55, 1240-1243.	2.9	16
880	CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials. <i>European Journal of Heart Failure</i> , 2013, 15, 747-755.	2.9	16
881	Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). <i>European Journal of Heart Failure</i> , 2015, 17, 707-716.	2.9	16
882	Predictive Value of Endostatin in Chronic Heart Failure Patients with Poor Kidney Function. <i>Cardiology</i> , 2015, 130, 17-22.	0.6	16

#	ARTICLE	IF	CITATIONS
883	Clinical characteristics and outcomes of patients with angina and heart failure in the <scp>CHARM</scp> (Candesartan in Heart Failure Assessment of Reduction in Mortality and) Tj ETQq1 1 0.784314.0 BT /Overlock 10	2.9	16
884	Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 240-247.	2.9	16
885	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	0.7	16
886	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020, 22, 1133-1143.	2.9	16
887	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. <i>Journal of Cardiac Failure</i> , 2021, 27, 670-676.	0.7	16
888	Reâ€examining the widespread policy of stopping sodiumâ€glucose cotransporterâ€2 inhibitors during acute illness: A perspective based on the updated evidence. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2071-2080.	2.2	16
889	Neuroendocrine changes post myocardial infarction: Effects of xamoterol. <i>American Heart Journal</i> , 1990, 120, 56-62.	1.2	15
890	Effects of resistive breathing on exercise capacity and diaphragm function in patients with ischaemic heart disease. <i>European Journal of Heart Failure</i> , 1999, 1, 297-300.	2.9	15
891	Venous endothelin receptor function in patients with chronic heart failure. <i>Clinical Science</i> , 2000, 98, 65-70.	1.8	15
892	It cannot be cardiac failure because the heart is not enlarged on the chest X-ray. <i>European Journal of Heart Failure</i> , 2003, 5, 117-119.	2.9	15
893	Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial). <i>American Journal of Cardiology</i> , 2009, 104, 151-157.	0.7	15
894	Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure â€“ Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , 2010, 12, 738-745.	2.9	15
895	Digitalis for treatment of heart failure in patients in sinus rhythm. <i>The Cochrane Library</i> , 2014, , CD002901.	1.5	15
896	It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non-ischaemic LVSD?. <i>European Heart Journal</i> , 2015, 36, 2047-2049.	1.0	15
897	ESRD After Heart Failure, Myocardial Infarction, or Stroke in TypeÂ2 Diabetic Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2017, 70, 522-531.	2.1	15
898	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1560-1562.	1.6	15
899	Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes. <i>Circulation</i> , 2018, 137, 1218-1220.	1.6	15
900	Post hoc analyses of SHIFT and PARADIGMâ€HF highlight the importance of chronic Chagas' cardiomyopathy <i>Comment on:</i> â€œSafety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trialâ€•by Bocchi <i>et al.</i>. <i>ESC Heart Failure</i> , 2018, 5, 1069-1071.	1.4	15

#	ARTICLE	IF	CITATIONS
901	Estimating the Lifetime Benefits of Treatments for Heart Failure. JACC: Heart Failure, 2020, 8, 984-995.	1.9	15
902	The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. ESC Heart Failure, 2020, 7, 1595-1604.	1.4	15
903	Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2021, 10, e022069.	1.6	15
904	Winter Peaks in Heart Failure: An Inevitable or Preventable Consequence of Seasonal Vulnerability?. Cardiac Failure Review, 2019, 5, 83-85.	1.2	15
905	Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in Denmark from 2003 to 2017. European Journal of Heart Failure, 2022, 24, 539-547.	2.9	15
906	Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF. European Journal of Heart Failure, 2022, 24, 794-803.	2.9	15
907	Re-emergence of heart failure with a normal ejection fraction?. European Heart Journal, 2022, 43, 427-429.	1.0	15
908	Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. European Heart Journal, 2022, 43, 5006-5016.	1.0	15
909	EFFECT OF DIARRHOEA ON A PATIENT TAKING CAPTOPRIL. Lancet, The, 1985, 325, 581.	6.3	14
910	Atrial natriuretic factor inhibits ACTH stimulated aldosterone, but not cortisol, secretion in man. European Journal of Clinical Pharmacology, 1988, 35, 409-412.	0.8	14
911	Angiotensin inhibition in heart failure.. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2004, 5, S17.	1.0	14
912	Increasing Awareness and Perception of Heart Failure in Europe and Improving Care: Rationale and Design of the SHAPE Study. Cardiovascular Drugs and Therapy, 2004, 18, 153-159.	1.3	14
913	Pharmacological treatment of heart failure with preserved ejection fraction: a glimpse of light at the end of the tunnel?. European Journal of Heart Failure, 2013, 15, 5-8.	2.9	14
914	Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF. International Journal of Cardiology, 2014, 177, 840-846.	0.8	14
915	Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction) Tj ETQq1 1 0.784314rgBT / Overlock 10		
916	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. European Journal of Heart Failure, 2020, 22, 2370-2379.	2.9	14
917	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure. Circulation: Heart Failure, 2020, 13, e007879.	1.6	14
918	Cardiorenal risk reduction guidance in diabetes: can we reach consensus?. Lancet Diabetes and Endocrinology, the, 2020, 8, 357-360.	5.5	14

#	ARTICLE	IF	CITATIONS
919	Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. <i>European Journal of Heart Failure</i> , 2020, 22, 848-855.	2.9	14
920	Quantification of pleural effusions on thoracic ultrasound in acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 513-521.	0.4	14
921	<sc>SOLOISTâ€ˆWHF</sc> and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 27-30.	2.9	14
922	Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. <i>Circulation</i> , 2021, 143, 2316-2318.	1.6	14
923	<sc>Angiotensinâ€ˆneprilysin</sc> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1591-1598.	2.9	14
924	Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	14
925	Poles apart, but are they the same? A comparative study of Australian and Scottish patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2001, 3, 249-255.	2.9	13
926	Carvedilol reduces the costs of medical care in severe heart failure: An economic analysis of the COPERNICUS study applied to the United Kingdom. <i>International Journal of Cardiology</i> , 2005, 100, 143-149.	0.8	13
927	Cardiac and Extracardiac Abnormalities Detected by Cardiac Magnetic Resonance in a Post-Myocardial Infarction Cohort. <i>Cardiology</i> , 2009, 113, 1-8.	0.6	13
928	What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?. <i>Open Heart</i> , 2015, 2, e000283.	0.9	13
929	Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the <sc>NAVIGATOR</sc> trial. <i>Diabetic Medicine</i> , 2015, 32, 1090-1096.	1.2	13
930	Site selection for heart failure clinical trials in the USA. <i>Heart Failure Reviews</i> , 2015, 20, 375-383.	1.7	13
931	Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemiaâ€ˆthe Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). <i>Journal of Human Hypertension</i> , 2016, 30, 46-52.	1.0	13
932	Hyporesponsiveness to Darbeoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbeoetin Alfa in Heart Failure). <i>Circulation: Heart Failure</i> , 2018, 11, e004431.	1.6	13
933	Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. <i>Diabetologia</i> , 2018, 61, 581-588.	2.9	13
934	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2021, 14, e008052.	1.6	13
935	Haemodynamic effects of the nitroxyl donor cimlanod (<sc>BMS</sc>â€ˆ986231) in chronic heart failure: a randomized trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1147-1155.	2.9	13
936	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGONâ€ˆHF. <i>Journal of the American Heart Association</i> , 2021, 10, e021494.	1.6	13

#	ARTICLE	IF	CITATIONS
937	Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment. <i>Kidney International</i> , 2005, 68, 1419-1426.	2.6	12
938	Aspirin Inhibits the Acute Arterial and Venous Vasodilator Response to Captopril in Patients with Chronic Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 261-265.	1.3	12
939	Does Aspirin Reduce the Benefit of an Angiotensin-Converting Enzyme Inhibitor?. <i>Circulation</i> , 2006, 113, 2566-2568.	1.6	12
940	Evaluation of the Functional Status Questionnaire in Heart Failure: A Sub-study of the Second Cardiac Insufficiency Bisoprolol Survival Study (CIBIS-II). <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 77-85.	1.3	12
941	Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. <i>European Journal of Heart Failure</i> , 2013, 15, 1253-1261.	2.9	12
942	Novel Extracellular Matrix Biomarkers as Predictors of Adverse Outcome in Chronic Heart Failure: Association Between Biglycan and Response to Statin Therapy in the CORONA Trial. <i>Journal of Cardiac Failure</i> , 2015, 21, 153-159.	0.7	12
943	Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	12
944	Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the <sc>EMPHASISâ€œHF</sc> study. <i>European Journal of Heart Failure</i> , 2016, 18, 1175-1181.	2.9	12
945	Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits. <i>JACC: Heart Failure</i> , 2017, 5, 591-599.	1.9	12
946	Optimizing heart failure treatment following cardiac resynchronization therapy. <i>Clinical Research in Cardiology</i> , 2020, 109, 638-645.	1.5	12
947	Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. <i>Journal of Hypertension</i> , 2020, 38, 420-425.	0.3	12
948	Adherence to prescribed medications in patients with heart failure: insights from liquid chromatographyâ€œtandem mass spectrometry-based urine analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 296-301.	1.4	12
949	Serum potassium and outcomes in heart failure with preserved ejection fraction: a postâ€œhoc analysis of the <sc>PARAGONâ€œHF</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 776-784.	2.9	12
950	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1298-1305.	3.0	12
951	Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretionâ€œin healthy humans. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 165-168.	1.1	11
952	The year in heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2398-2405.	1.2	11
953	Heart Failure Management Programs Reduce Readmissions and Prolong Survival. <i>Archives of Internal Medicine</i> , 2005, 165, 1311.	4.3	11
954	Dysglycemia and Heart Failure Hospitalization. <i>Circulation</i> , 2007, 115, 1334-1335.	1.6	11

#	ARTICLE	IF	CITATIONS
955	Dual Renin-Angiotensin System Blockade and Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2009, 54, 278-279.	1.2	11
956	Evaluating dyspnoea in acute heart failure: progress at last!. <i>European Heart Journal</i> , 2010, 31, 771-772.	1.0	11
957	The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics. <i>European Journal of Heart Failure</i> , 2011, 13, 917-924.	2.9	11
958	Gut Feelings About Heart Failure— <i>Journal of the American College of Cardiology</i> , 2014, 64, 1915-1916.	1.2	11
959	Chronic obstructive pulmonary disease and cardiovascular risk: Insights from the NAVIGATOR trial. <i>International Journal of Cardiology</i> , 2014, 176, 1126-1128.	0.8	11
960	High-Sensitivity Troponin T and Incident Heart Failure in Older Men: British Regional Heart Study. <i>Journal of Cardiac Failure</i> , 2019, 25, 230-237.	0.7	11
961	Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2019, 25, 703-711.	0.7	11
962	Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2019, 108, 868-877.	1.5	11
963	The year in cardiology: heart failure. <i>European Heart Journal</i> , 2020, 41, 1232-1248.	1.0	11
964	Covariate adjusted reanalysis of the I-Preserve trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1358-1365.	1.5	11
965	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 1346-1356.	2.9	11
966	Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy. <i>JACC: Heart Failure</i> , 2021, 9, 386-397.	1.9	11
967	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021, 8, 5531-5541.	1.4	11
968	The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1824-1832.	2.2	11
969	Health Status Trajectories Before and After Hospitalization for Heart Failure. <i>Circulation</i> , 2022, 145, 1872-1874.	1.6	11
970	Final Consensus Statement of the Royal College of Physicians of Edinburgh Consensus Conference on Atrial Fibrillation in Hospital and General Practice, 3-4 September 1998. <i>British Journal of Haematology</i> , 1999, 104, 195-196.	1.2	10
971	Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial infarction (VALIANT) trial. <i>American Heart Journal</i> , 2006, 152, 500-508.	1.2	10
972	Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials. <i>Cardiovascular Therapeutics</i> , 2010, 28, 124-132.	1.1	10

#	ARTICLE	IF	CITATIONS
973	Interleukin-21 "A biomarker of importance in predicting myocardial function following acute infarction?. Cytokine, 2012, 60, 220-225.	1.4	10
974	Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure. Journal of Hypertension, 2018, 36, 1736-1742.	0.3	10
975	Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study. Clinical Epidemiology, 2018, Volume 10, 917-930.	1.5	10
976	N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. Diabetes, Obesity and Metabolism, 2018, 20, 2899-2904.	2.2	10
977	Baseline Characteristics of the VANISH Cohort. Circulation: Heart Failure, 2019, 12, e006231.	1.6	10
978	Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure. Circulation: Heart Failure, 2020, 13, e008007.	1.6	10
979	Response by Jackson et al to Letter Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF". Circulation, 2020, 142, e5-e6.	1.6	10
980	Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. Diabetes, Obesity and Metabolism, 2021, 23, 561-568.	2.2	10
981	Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrology Dialysis Transplantation, 2022, 37, 960-972.	0.4	10
982	The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). European Journal of Heart Failure, 2021, 23, 1052-1056.	2.9	10
983	Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study. International Journal of Cardiology, 2021, 330, 91-97.	0.8	10
984	Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. JACC: Heart Failure, 2022, 10, 52-64.	1.9	10
985	Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. European Heart Journal, 2022, 43, 2212-2220.	1.0	10
986	Relationship of Dapagliflozin With Serum Sodium. JACC: Heart Failure, 2022, 10, 306-318.	1.9	10
987	Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes. , 2022, 1, .		10
988	The reproducibility of symptoms during a submaximal exercise test in chronic heart failure. British Journal of Clinical Pharmacology, 1998, 45, 287-290.	1.1	9
989	Novel neuropeptides in the pathophysiology of heart failure: adrenomedullin and endothelin-1. European Journal of Heart Failure, 1999, 1, 25-29.	2.9	9
990	Effect of Rosuvastatin on Fatigue in Patients With Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1121-1122.	1.2	9

#	ARTICLE	IF	CITATIONS
991	Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. <i>European Heart Journal</i> , 2013, 34, 1621-1629.	1.0	9
992	ECG "Still the Best for Selecting Patients for CRT. <i>New England Journal of Medicine</i> , 2013, 369, 1463-1464.	13.9	9
993	β^2 blockers, atrial fibrillation, and heart failure. <i>Lancet, The</i> , 2014, 384, 2181-2183.	6.3	9
994	The association between meteorological events and acute heart failure: New insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014, 177, 819-824.	0.8	9
995	Venous Thromboembolism and Cardiovascular Risk: Results from the NAVIGATOR Trial. <i>American Journal of Medicine</i> , 2015, 128, 297-302.	0.6	9
996	Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2016, 22, 409-416.	0.7	9
997	Clinical Trials Involving Hypertension. <i>New England Journal of Medicine</i> , 2017, 376, 289-290.	13.9	9
998	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 512-519.	0.7	9
999	Redefining heart failure phenotypes based on ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 1634-1635.	2.9	9
1000	Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2019, 281, 179-185.	0.8	9
1001	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. <i>ESC Heart Failure</i> , 2020, 7, 3355-3364.	1.4	9
1002	Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e007814.	1.6	9
1003	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. <i>ESC Heart Failure</i> , 2021, 8, 129-138.	1.4	9
1004	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the <sc>HEAAL</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1477-1484.	2.9	9
1005	Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. <i>JACC: Heart Failure</i> , 2021, 9, 518-527.	1.9	9
1006	Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2900-2911.	3.0	9
1007	Drug therapy for heart failure with reduced ejection fraction: what is the "right" dose?. <i>European Journal of Heart Failure</i> , 2022, 24, 421-430.	2.9	9
1008	Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. <i>Clinical Science</i> , 2001, 101, 45.	1.8	8

#	ARTICLE	IF	CITATIONS
1009	Effect of Neutral Endopeptidase Inhibition on the Actions of Adrenomedullin and Endothelin-1 in Resistance Arteries From Patients With Chronic Heart Failure. <i>Hypertension</i> , 2001, 38, 412-416.	1.3	8
1010	The statin wars. <i>Lancet</i> , The, 2003, 362, 1854.	6.3	8
1011	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversi3n de la angiotensina en la enfermedad cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2004, 57, 1213-1232.	0.6	8
1012	Predictors of Stroke in Patients With Impaired Glucose Tolerance. <i>Stroke</i> , 2013, 44, 2590-2593.	1.0	8
1013	Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). <i>Biomarkers</i> , 2017, 22, 261-267.	0.9	8
1014	Change in Hemoglobin Trajectory and Darbeopetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. <i>American Journal of Nephrology</i> , 2017, 46, 488-497.	1.4	8
1015	Cost-Effectiveness Analysis of Natriuretic Peptide Testing and Specialist Management in Patients with Suspected Acute Heart Failure. <i>Value in Health</i> , 2017, 20, 1025-1033.	0.1	8
1016	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2021, 110, 1234-1248.	1.5	8
1017	Captopril and Norepinephrine-Induced Hypertrophy and Haemodynamics in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 27, 667-672.	0.8	8
1018	Qu3telet (body mass) index and effects of dapagliflozin in chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 827-837.	2.2	8
1019	Unique cardioprotective potential of angiotensin converting enzyme inhibitors: a hypothesis still to be tested on humans. <i>Journal of Hypertension</i> , 1991, 9, 393-397.	0.3	7
1020	ACE inhibitors and health-care economics. <i>Coronary Artery Disease</i> , 1995, 6, 315-320.	0.3	7
1021	Cardiac cachexia3lean and mean. <i>European Heart Journal</i> , 1999, 20, 1609-1611.	1.0	7
1022	Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. <i>Clinical Science</i> , 2001, 101, 45-51.	1.8	7
1023	Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2002, 53, 37-42.	1.1	7
1024	Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?. <i>European Heart Journal</i> , 2004, 25, 357-358.	1.0	7
1025	A putative placebo comparison of the SCOPE and LIFE trials. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, 59-63.	1.0	7
1026	Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. <i>Country Review Ukraine</i> , 2005, 7, C41-C54.	0.8	7

#	ARTICLE	IF	CITATIONS
1027	Angiotensin receptor blockers and myocardial infarction. <i>BMJ: British Medical Journal</i> , 2005, 330, 1269.1.	2.4	7
1028	Calcium Handling in the Failing Heart and SUMO – Weighing the Evidence. <i>New England Journal of Medicine</i> , 2011, 365, 1738-1739.	13.9	7
1029	Clinical Outcomes at 180 days in the ASCEND-HF Trial: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 971.	0.7	7
1030	Darbepoetin Alfa in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2013, 369, 487-489.	13.9	7
1031	Why and when should we worry about worsening renal function?. <i>European Journal of Heart Failure</i> , 2014, 16, 4-5.	2.9	7
1032	Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. <i>BMJ Open</i> , 2015, 5, e007901.	0.8	7
1033	Effect of valsartan on kidney outcomes in people with impaired glucose tolerance. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 791-799.	2.2	7
1034	Lung ultrasound: monitoring congestion in patients with heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1614-1615.	2.9	7
1035	The importance of randomised vs non-randomised trials – Authors' reply. <i>Lancet</i> , The, 2019, 394, 635.	6.3	7
1036	Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. <i>European Journal of Heart Failure</i> , 2019, 21, 699-702.	2.9	7
1037	<sc>EMPEROR</sc> – Reduced: confirming sodium – glucose co – transporter 2 inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1987-1990.	2.9	7
1038	High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. <i>Cardiovascular Research</i> , 2023, 119, 213-220.	1.8	7
1039	Sex differences in congestive markers in patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , 2021, 8, 1784-1795.	1.4	7
1040	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in <sc>EMPHASIS – HF</sc> and <sc>RALES</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 529-538.	2.9	7
1041	Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. <i>Kidney360</i> , 2021, 2, 10.34067/KID.0004272021.	0.9	7
1042	Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 750-760.	1.8	7
1043	Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate. <i>European Journal of Heart Failure</i> , 2022, 24, 861-866.	2.9	7
1044	Insights into foundational therapies for heart failure with reduced ejection fraction. <i>Clinical Cardiology</i> , 2022, 45, .	0.7	7

#	ARTICLE	IF	CITATIONS
1045	Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score. <i>JACC: Heart Failure</i> , 2022, 10, 543-555.	1.9	7
1046	Furosemide pretreatment blunts the inhibition of renal tubular sodium reabsorption by ANF in man. <i>European Journal of Clinical Pharmacology</i> , 1988, 35, 333-338.	0.8	6
1047	Endothelin Receptor Antagonists and Cardiovascular Diseases of Aging. <i>Drugs and Aging</i> , 2001, 18, 425-439.	1.3	6
1048	Effect of Aliskiren in Patients with Heart Failure According to Background Dose of ACE Inhibitor: A Retrospective Analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 315-321.	1.3	6
1049	Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. <i>BMC Neurology</i> , 2015, 15, 3.	0.8	6
1050	Efficacy of LCZ696 Persists at Lower Than Target Doses in the PARADIGM-HF Trial. <i>Journal of Cardiac Failure</i> , 2015, 21, S9-S10.	0.7	6
1051	T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. <i>Clinical Research in Cardiology</i> , 2019, 108, 133-141.	1.5	6
1052	Estimated Long-Term Survival With Eplerenone. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2357-2359.	1.2	6
1053	Do We Need Clinical Events Committees to Adjudicate End Points?. <i>Circulation: Heart Failure</i> , 2020, 13, e007209.	1.6	6
1054	Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease. <i>European Journal of Heart Failure</i> , 2020, 22, 813-820.	2.9	6
1055	Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 693-695.	0.7	6
1056	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	1.4	6
1057	Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF. <i>European Journal of Heart Failure</i> , 2022, 24, 672-677.	2.9	6
1058	Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. <i>Kidney International Reports</i> , 2022, 7, 699-707.	0.4	6
1059	Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". <i>Circulation</i> , 2021, 144, e40.	1.6	6
1060	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. <i>American Heart Journal</i> , 2022, 251, 13-24.	1.2	6
1061	Elevated serum and monocyte tumour necrosis factor alpha in patients with congestive heart failure. <i>International Journal of Cardiology</i> , 1999, 71, 263-264.	0.8	5
1062	Angiotensin receptor blockers in heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003, 4, 171-175.	1.0	5

#	ARTICLE	IF	CITATIONS
1063	EXPERT CONSENSUS DOCUMENT ON ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE. <i>Rational Pharmacotherapy in Cardiology</i> , 2005, 1, 49-69.	0.3	5
1064	Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 128-129.	3.3	5
1065	QRS duration alone to select patients for cardiac resynchronization therapy: flying in the face of the evidence?. <i>European Heart Journal</i> , 2006, 27, 3074-3075.	1.0	5
1066	HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure—lessons learnt from a decade of trials. <i>European Journal of Heart Failure</i> , 2010, 12, 99-103.	2.9	5
1067	Prediabetes and the risk of diabetes. <i>Lancet, The</i> , 2012, 380, 1225-1226.	6.3	5
1068	The Angiotensin Receptor Nephilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial. <i>Journal of Cardiac Failure</i> , 2012, 18, 883.	0.7	5
1069	A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2013, 112, 231-237.	0.7	5
1070	Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2013, 15, 1205-1207.	2.9	5
1071	Updated risk factors should be used to predict development of diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 859-863.	1.2	5
1072	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. <i>American Heart Journal</i> , 2018, 199, 170-175.	1.2	5
1073	Who Benefits From a Defibrillator—Balancing the Risk of Sudden Versus Non-sudden Death. <i>Current Heart Failure Reports</i> , 2018, 15, 376-389.	1.3	5
1074	Talking to patients with heart failure about end of life. <i>European Journal of Heart Failure</i> , 2018, 20, 1763-1765.	2.9	5
1075	Prognostic Modeling in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 463-464.	1.9	5
1076	Only Trials Tell the Truth About Treatment Effects. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2640-2642.	1.2	5
1077	Phosphodiesterase-9 Inhibition in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, 902-904.	1.2	5
1078	Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. <i>Clinical Research in Cardiology</i> , 2019, 108, 806-814.	1.5	5
1079	Chagas disease: still a neglected emergency?. <i>Lancet, The</i> , 2020, 395, 1113-1114.	6.3	5
1080	Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1631-1638.	2.3	5

#	ARTICLE	IF	CITATIONS
1081	Influence of Study Discontinuation during the Run-in Period on the Estimated Efficacy of Sacubitril/valsartan in the PARAGON-HF Trial. <i>European Journal of Heart Failure</i> , 2021, , .	2.9	5
1082	Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure. <i>CJC Open</i> , 2020, 2, 135-144.	0.7	5
1083	Clinical Trials Report: Cardiovascular & Renal: Ongoing and planned clinical trials in chronic heart failure and left ventricular dysfunction. <i>Expert Opinion on Investigational Drugs</i> , 1995, 4, 1069-1080.	1.9	5
1084	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. <i>JACC: Heart Failure</i> , 2022, 10, 104-118.	1.9	5
1085	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. <i>Journal of the American Heart Association</i> , 2022, 11, e021327.	1.6	5
1086	The ASCEND-ND trial: study design and participant characteristics. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2157-2170.	0.4	5
1087	Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry. <i>JACC: Heart Failure</i> , 2022, 10, 380-392.	1.9	5
1088	Beta-blockers, ventricular arrhythmias, and sudden death in heart failure: not as simple as it seems. <i>European Heart Journal</i> , 2000, 21, 1214-1215.	1.0	4
1089	Myocardial Infarct. <i>Circulation</i> , 2002, 105, 2577-2579.	1.6	4
1090	The CHARM programme. <i>Lancet</i> , 2003, 362, 1678-1679.	6.3	4
1091	Aldosterone blockade in post-acute myocardial infarction heart failure. <i>Clinical Cardiology</i> , 2006, 29, 434-438.	0.7	4
1092	Corrigendum to "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008" [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. <i>European Journal of Heart Failure</i> , 2009, 11, 110-110.	2.9	4
1093	'Iron deficiency: an ominous sign in patients with systolic chronic heart failure' [Eur Heart J 2010;31:1872-1880, doi:10.1093/eurheartj/ehq158]. <i>European Heart Journal</i> , 2011, 32, 1054-1054.	1.0	4
1094	Prognostic value of CXCL16 in patients with left ventricular systolic dysfunction and heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 4427-4429.	0.8	4
1095	Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	4
1096	Aliskiren, Enalapril, or Both in Heart Failure. <i>New England Journal of Medicine</i> , 2016, 375, 701-702.	13.9	4
1097	Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2488-2490.	1.2	4
1098	The Effect of Omecamtiv Mecarbil on Symptoms of Heart Failure in the Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF). <i>Journal of Cardiac Failure</i> , 2016, 22, S10-S11.	0.7	4

#	ARTICLE	IF	CITATIONS
1099	International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	4
1100	EFFECT OF SACUBITRIL/VALSARTAN COMPARED WITH ENALAPRIL, ACCORDING TO ETIOLOGY IN PARADIGM-HF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 919.	1.2	4
1101	Effects of apixaban compared with warfarin as gain in event-free time – a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1311-1319.	0.8	4
1102	Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. <i>Diabetes Research and Clinical Practice</i> , 2020, 170, 108488.	1.1	4
1103	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. <i>Clinical Research in Cardiology</i> , 2021, 110, 1334-1349.	1.5	4
1104	Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF. <i>Clinical Research in Cardiology</i> , 2021, 111, 440.	1.5	4
1105	Concise Guide to the Management of Heart Failure - World Health Organization/Council on Geriatric Cardiology Task Force on Heart Failure Education. <i>The American Journal of Geriatric Cardiology</i> , 1996, 5, 13-30.	0.7	4
1106	Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. <i>JACC: Heart Failure</i> , 2022, 10, 415-427.	1.9	4
1107	Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 498-507.	1.9	4
1108	Factors associated with health-related quality of life in heart failure in 23,000 patients from 40 countries: Results of the CHF Research Program. <i>European Journal of Heart Failure</i> , 2022, , .	2.9	4
1109	The J-curve hypothesis. <i>Lancet, The</i> , 1992, 339, 561-562.	6.3	3
1110	ACE inhibitors for myocardial infarction and unstable angina. <i>Lancet, The</i> , 1992, 340, 1547-1549.	6.3	3
1111	Effects of the xanthine oxidase system on cardiac function in anaesthetised rats. <i>Free Radical Biology and Medicine</i> , 1993, 15, 249-255.	1.3	3
1112	ACE Inhibitors after myocardial Infarction. <i>Lancet, The</i> , 1993, 342, 1418-1419.	6.3	3
1113	EARTH: Endothelin _A Receptor Antagonist Trial in Heart Failure. <i>Cardiology</i> , 2001, 1, 294-298.	0.3	3
1114	Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001, 2, 89-92.	1.0	3
1115	Beta-blockers and heart failure in older people: reply. <i>European Heart Journal</i> , 2006, 27, 888-889.	1.0	3
1116	Pharmacologic management of patients with both heart failure and diabetes. <i>Current Heart Failure Reports</i> , 2009, 6, 126-132.	1.3	3

#	ARTICLE	IF	CITATIONS
1117	Heart failure therapyâ€”technology to the fore. <i>Nature Reviews Cardiology</i> , 2012, 9, 73-74.	6.1	3
1118	DO COUNTRIES OR HOSPITALS WITH LONGER STAYS HAVE LOWER READMISSION RATES? FINDINGS FROM THE ASCEND-HF TRIAL. <i>Journal of the American College of Cardiology</i> , 2012, 59, E1029.	1.2	3
1119	Corrigendum to â€œAnalysing recurrent hospitalizations in heart failure: a review ofâ€”statistical methodology, with application toâ€”CHARM-Preservedâ€” [Eur J Heart Fail2014;16:33-40]. <i>European Journal of Heart Failure</i> , 2014, 16, 592-592.	2.9	3
1120	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 295-301.	1.3	3
1121	Evidence-Based Therapy and Its Association With Workforce Detachment After First Hospitalization for Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 41-48.	1.9	3
1122	Prevalence and profile of â€œseasonal frequent flyersâ€”with chronic heart disease: Analysis of 1598 patients and 4588 patient-years follow-up. <i>International Journal of Cardiology</i> , 2019, 279, 126-132.	0.8	3
1123	Angiotensin receptorâ€”neprilysin inhibition in heart failure with preserved ejection fraction: lessons from <sc>PARAGONâ€”HF</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 1525-1530.	2.9	3
1124	Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2021, 110, 1308-1320.	1.5	3
1125	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008075.	1.6	3
1126	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021, 237, 45-53.	1.2	3
1127	Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. <i>PLoS ONE</i> , 2021, 16, e0255364.	1.1	3
1128	Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 127-131.	0.4	3
1129	Prognostic value of cardiac magnetic resonance parameters and biomarkers following myocardial infarction; 10â€”year followâ€”up of the Eplerenone Remodelling in Myocardial Infarction without Heart Failure trial. <i>European Journal of Heart Failure</i> , 2022, 24, 393-395.	2.9	3
1130	Clinical characteristics and survival in patients with heart failure experiencing in hospital cardiac arrest. <i>Scientific Reports</i> , 2022, 12, 5685.	1.6	3
1131	Pharmacogenomic study of heart failure and candesartan response from the CHARM programme. <i>ESC Heart Failure</i> , 2022, 9, 2997-3008.	1.4	3
1132	Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. <i>Diabetes Care</i> , 2022, 45, 2152-2155.	4.3	3
1133	Atrial Natriuretic Factor Attenuates Prostaglandin E2-Stimulated Plasma Renin Activity in Humans. <i>Journal of Cardiovascular Pharmacology</i> , 1989, 14, 326-330.	0.8	2
1134	Effects of xamoterol in acute myocardial infarction: blood pressure, heart rate, arrhythmias and early clinical course. <i>International Journal of Cardiology</i> , 1991, 31, 295-303.	0.8	2

#	ARTICLE	IF	CITATIONS
1135	Acute heart failure: a practical guide to management. British Journal of Hospital Medicine, 2000, 61, 725-729.	0.3	2
1136	Amlodipine for all undergoing PCI? The evidence is unconvincing. International Journal of Cardiology, 2002, 84, 30-32.	0.8	2
1137	17Å Oestradiol Does Not Attenuate the Response to Angiotensin I and II During Long Term Therapy in Postmenopausal Women. Cardiovascular Drugs and Therapy, 2004, 18, 31-36.	1.3	2
1138	Ximelagatran Compared with Warfarin for the Prevention of Systemic Embolism and Stroke. An Imputed Placebo Analysis. Cardiovascular Drugs and Therapy, 2005, 19, 149-151.	1.3	2
1139	The role of angiotensin II receptor blockers in the management of heart failure. Country Review Ukraine, 2005, 7, J10-J14.	0.8	2
1140	Chilling Findings: The Need for Winter Vigilance in Heart Failure. Journal of Cardiac Failure, 2006, 12, 120-121.	0.7	2
1141	Microvolt T-Wave Alternans Testing Has No Role at Present in Guiding Therapy for Patients at High Risk of Ventricular Arrhythmias. Journal of the American College of Cardiology, 2012, 59, 856.	1.2	2
1142	Aliskiren in Type 2 Diabetes and Cardiorenal End Points. New England Journal of Medicine, 2013, 368, 1064-1066.	13.9	2
1143	Response to Letter Regarding Article, "Galectin-3 and Cardiac Function in Survivors of Acute Myocardial Infarction". Circulation: Heart Failure, 2013, 6, e58.	1.6	2
1144	Acute heart failure: have we got it all wrong?. European Journal of Heart Failure, 2014, 16, 1263-1267.	2.9	2
1145	Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. Diabetes, Obesity and Metabolism, 2014, 16, 1265-1268.	2.2	2
1146	Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials". Circulation, 2015, 132, e358.	1.6	2
1147	Trials and the "real world" - how different are they?. European Journal of Heart Failure, 2016, 18, 411-413.	2.9	2
1148	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. Journal of the American Heart Association, 2017, 6, .	1.6	2
1149	PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Cardiovascular Research, 2019, 115, e136-e139.	1.8	2
1150	Urinalysis. JACC: Heart Failure, 2019, 7, 402-403.	1.9	2
1151	<sc>VICTORIA</sc> in context. European Journal of Heart Failure, 2020, 22, 1747-1751.	2.9	2
1152	Anticoagulation, atherothrombosis, and heart failure: lessons from COMMANDER-HF and CORONA. European Heart Journal, 2021, 42, e5-e7.	1.0	2

#	ARTICLE	IF	CITATIONS
1153	Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia, 2022, , .	0.5	2
1154	Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 2022, 9, 3655-3658.	1.4	2
1155	The place of ACE inhibitors in the current treatment of chronic heart failure. Postgraduate Medical Journal, 1988, 64, 653-655.	0.9	1
1156	The Place of Angiotensin-Converting Enzyme Inhibitors in Internal Medicine. Medical Principles and Practice, 1989, 1, 65-70.	1.1	1
1157	Neurohumoral aspects of heart failure. Current Opinion in Cardiology, 1989, 4, 355-359.	0.8	1
1158	Impaired vascular responsiveness to nitric oxide in renal transplant recipients. Transplantation Proceedings, 1999, 31, 304-305.	0.3	1
1159	Why we Need New Strategies in CHF Management. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 12-16.	1.0	1
1160	Ongoing clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 131-136.	1.0	1
1161	Older and more complicated heart failure patients: an increasing challenge to the health care system!. Coronary Health Care, 2001, 5, 121-125.	0.4	1
1162	Drug Safety in Cardiovascular Disease: A Call to ACTION. Cardiovascular Drugs and Therapy, 2006, 20, 9-10.	1.3	1
1163	Heart failure: are we neglecting the silent majority?. European Heart Journal, 2007, 28, 1047-1048.	1.0	1
1164	Pathogenesis of Atherosclerosis and Vascular Disease in Type 2 Diabetes. , 0, , 16-36.		1
1165	Prevention of Diabetes as a Means of Preventing Cardiovascular Disease. , 0, , 240-257.		1
1166	Diabetes for Cardiologists. , 0, , 258-279.		1
1167	Response to Letter Regarding Article, "Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure". Circulation, 2008, 118, .	1.6	1
1168	Dual Renin-Angiotensin System Blockade in Heart Failure. Journal of the American College of Cardiology, 2009, 54, 278.	1.2	1
1169	Event Rates in Trials of Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2010, 303, 732.	3.8	1
1170	Corrigendum to "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008" [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. European Journal of Heart Failure, 2010, 12, 416-416.	2.9	1

#	ARTICLE	IF	CITATIONS
1171	Comparative Effectiveness of Angiotensinâ€‘Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study. <i>Journal of Clinical Hypertension</i> , 2012, 14, 731-731.	1.0	1
1172	Response to Letter Regarding Article, â€‘Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillationâ€‘. <i>Circulation</i> , 2014, 129, e21-2.	1.6	1
1173	Treatment of severe hypertriglyceridaemia. <i>Lancet Diabetes and Endocrinology</i> ,the, 2014, 2, 860.	5.5	1
1174	End of the Road for Vagus Nerve Stimulation? â€‘. <i>Journal of the American College of Cardiology</i> , 2016, 68, 159-160.	1.2	1
1175	Disease Management Programs in Cardiology. <i>Circulation</i> , 2016, 133, 1836-1837.	1.6	1
1176	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016, 1, 93-100.	2.7	1
1177	CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: INSIGHTS FROM PARADIGM-HF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 734.	1.2	1
1178	Effect of Omecamtiv Mecarbil in Patients with Ischemic and Non-Ischemic Heart Failure with Reduced Ejection Fraction: Results From COSMIC-HF. <i>Journal of Cardiac Failure</i> , 2017, 23, S11.	0.7	1
1179	Reply. <i>JACC: Heart Failure</i> , 2017, 5, 852-853.	1.9	1
1180	Risk stratification according to insulin type: reply. <i>European Journal of Heart Failure</i> , 2018, 20, 1498-1498.	2.9	1
1181	Proâ€‘gastrinâ€‘releasing peptide and outcome in patients with heart failure and anaemia: results from the REDâ€‘HF study. <i>ESC Heart Failure</i> , 2018, 5, 1052-1059.	1.4	1
1182	EFFECT OF OMECANTIV MECARBIL IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: RESULTS FROM COSMIC-HF. <i>Journal of the American College of Cardiology</i> , 2019, 73, 691.	1.2	1
1183	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 175.	2.7	1
1184	Diagnosing heart failure with preserved ejection fractionâ€‘â€‘What's the score?. <i>European Journal of Heart Failure</i> , 2020, 22, 425-427.	2.9	1
1185	MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	1
1186	Gender- and Age-Specific Rates of Heart Failure and other Adverse Cardiovascular Outcomes in Systemic Sclerosis. <i>Rheumatology</i> , 2022, , .	0.9	1
1187	Current management of heart failure. <i>Practitioner</i> , 2002, 246, 438-43.	0.3	1
1188	Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes. <i>Clinical Research in Cardiology</i> , 2022, , 1.	1.5	1

#	ARTICLE	IF	CITATIONS
1189	An analysis of vascular access thrombosis events from the Proactive IV Iron Therapy in Hemodialysis Patients (PIVOTAL) trial. <i>Kidney International Reports</i> , 2022, , .	0.4	1
1190	Epidemiology of Vascular Disease in Diabetes. , 0, , 1-15.		0
1191	The BP response to the first dose of captopril: Does the dose size matter and does it predict the BP response to subsequent doses?. <i>Journal of Molecular and Cellular Cardiology</i> , 1990, 22, S95.	0.9	0
1192	Silent myocardial ischemia: A critical appraisal. <i>International Journal of Cardiology</i> , 1991, 33, 182.	0.8	0
1193	Comparison of the effects of ANF 99â€™126 and ANF 103â€™126 on captoprilâ€™induced renin release in man. <i>Clinical Endocrinology</i> , 1991, 34, 493-499.	1.2	0
1194	Digoxin for patients with heart failure in sinus rhythm. <i>Lancet</i> , The, 1997, 350, 519.	6.3	0
1195	Prescribing and emergency admissions for heart failure in greater glasgow. <i>Journal of Cardiac Failure</i> , 1999, 5, 3-7.	0.7	0
1196	Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme. <i>Blood Pressure</i> , 2000, 9, 60-60.	0.7	0
1197	Review: Optimising the use of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2005, 6, S2-S5.	1.0	0
1198	¿CuÃ¡l deberÃa ser el fÃ¡rmaco que se aÃ±adiera a un IECA y un bloqueador beta en la insuficiencia cardiaca por disfunciÃ³n sistÃ3lica: un antagonista de la aldosterona o un ARA-II? Evidencias clÃnicas con ambos. <i>Revista Espanola De Cardiologia Suplementos</i> , 2006, 6, 29C-36C.	0.2	0
1199	Response to Letter Regarding Article, â€™Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomasâ€™. <i>Circulation</i> , 2007, 115, .	1.6	0
1200	Diabetes and Peripheral Arterial Disease. , 0, , 199-222.		0
1201	Diabetes and Hypertension. , 0, , 135-174.		0
1202	Coronary Heart Disease and Diabetes. , 0, , 37-67.		0
1203	Diabetes and Acute Coronary Syndromes. , 0, , 69-92.		0
1204	Corrigendum to â€™Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blockerâ€™[<i>European Journal of Heart Failure</i> 9/4 (2007) 429-434]. <i>European Journal of Heart Failure</i> , 2007, 9, 1074-1074.	2.9	0
1205	Study Acronyms. , 0, , 280-286.		0
1206	Diabetes, Left Ventricular Systolic Dysfunction and Chronic Heart Failure. , 0, , 93-134.		0

#	ARTICLE	IF	CITATIONS
1207	Diabetes and Stroke / Transient Ischaemic Attacks. , 0, , 175-198.		0
1208	Prevention of Cardiovascular Events in Diabetic Patients. , 0, , 223-239.		0
1209	Health Related Quality of Life in I-PRESERVE Trial. Journal of Cardiac Failure, 2008, 14, S73.	0.7	0
1210	Response to The J-Point Revisited. Hypertension, 2008, 51, .	1.3	0
1211	Medical management of advanced heart failure. Progress in Palliative Care, 2008, 16, 229-240.	0.7	0
1212	Should beta-blockade continue to be withheld from patients with chronic heart failure and asthma?: reply. European Heart Journal, 2009, 30, 1287-1288.	1.0	0
1213	Heart failure and chronic obstructive pulmonary disease: lung function test interpretation: reply. European Journal of Heart Failure, 2009, 11, 632-633.	2.9	0
1214	Corrigendum to "Design of the Reduction of Events with Darbeoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial" [Eur J Heart Fail 2009;11:795-801]. European Journal of Heart Failure, 2010, 12, 765-765.	2.9	0
1215	Hospital-at-home care for CHF-verdict, 'not proven'. Nature Reviews Cardiology, 2010, 7, 63-64.	6.1	0
1216	Acute ischemic events in HF-should we include sudden death?. Nature Reviews Cardiology, 2011, 8, 192-193.	6.1	0
1217	Response to Letter Regarding Article, "Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both": Circulation, 2011, 123, .	1.6	0
1218	Response to Letters Regarding Article, "Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction": Circulation, 2012, 126, .	1.6	0
1219	Feasibility/eligibility of T-wave alternans testing in patients with heart failure: should we rethink our current modus operandi?: reply. European Journal of Heart Failure, 2012, 14, 676-677.	2.9	0
1220	Microvolt T-wave alternans testing should be used to guide arrhythmic therapy in heart failure patients: reply. European Journal of Heart Failure, 2012, 14, 678-678.	2.9	0
1221	Reply to the letter by Dr Erqou regarding "Intensive glycemc control has no impact on the risk of heart failure in type 2 diabetic patients": American Heart Journal, 2012, 163, e37.	1.2	0
1222	Reply. Journal of the American College of Cardiology, 2013, 61, 1749.	1.2	0
1223	Letter by MacDonald et al Regarding Article, "Catheter Ablation of Atrial Fibrillation". Circulation, 2013, 127, e433.	1.6	0
1224	Microvolt T-wave alternans testing in patients recently hospitalized with decompensated heart failure. European Journal of Heart Failure, 2014, 16, 113-113.	2.9	0

#	ARTICLE	IF	CITATIONS
1225	Reply. Journal of the American College of Cardiology, 2014, 64, 1535-1536.	1.2	0
1226	The Clinical Implications of Cardiac Troponin I Measured by an "Ultrasensitive" Assay in Acute Decompensated Heart Failure: Insights from ASCEND-HF. Journal of Cardiac Failure, 2015, 21, S25-S26.	0.7	0
1227	Extra-Cardiac Disease Burden Contributes More Than Cardiac Disease Burden to Risk of Cardiovascular Outcomes in Patient with Preserved Ejection Fraction. Journal of Cardiac Failure, 2016, 22, S65-S66.	0.7	0
1228	Target Dose of Sacubitril/Valsartan Achieved in Most Patients with HFrEF Irrespective of Baseline SBP. Journal of Cardiac Failure, 2016, 22, S66.	0.7	0
1229	Sacubitril/Valsartan Associated with Lower Declines in Health-Related Quality of Life Compared with Enalapril in Patients with Heart Failure Hospitalization. Journal of Cardiac Failure, 2016, 22, S24.	0.7	0
1230	Improved Contractility and Evolution of Ventricular Remodelling Through Time in the Chronic Oral		

#	ARTICLE	IF	CITATIONS
1243	Reply. JACC: Heart Failure, 2020, 8, 597-598.	1.9	0
1244	Dyslipidaemia, a factor worthy of adjustment: reply. European Journal of Heart Failure, 2020, 22, 564-565.	2.9	0
1245	Reply. Journal of the American College of Cardiology, 2020, 75, 1501-1502.	1.2	0
1246	Considering dose in pharmacological therapies for heart failure – Authors' reply. Lancet, The, 2021, 397, 275.	6.3	0
1247	Sacubitril / valsartan for patients with heart failure with preserved ejection fraction: what will the FDA decide?. Kardiologia Polska, 2021, 79, 104-105.	0.3	0
1248	Reply. Journal of the American College of Cardiology, 2021, 78, 760-761.	1.2	0
1249	Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. Journal of Cardiac Failure, 2021, 27, 1027-1030.	0.7	0
1250	Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart, 2001, 86, 97-103.	1.2	0
1251	Clinical assessment and investigation of patients with suspected heart failure. , 2004, , 75-91.		0
1252	Discharge rates for suspected acute coronary syndromes: Authors' reply. BMJ: British Medical Journal, 2004, 329, 173.2.	2.4	0
1253	Heart Failure – Optimal Pharmacological Therapy. , 2008, , 49-74.		0
1254	The year in cardiology 2019: heart failure. Revista Romana De Cardiologie, 2020, 30, 185-204.	0.0	0
1255	Age-Adjusted Survival Extrapolations – Results May Differ From Those Generated by the Weibull Model – Reply. JAMA Cardiology, 2022, , .	3.0	0
1256	Can an implanted minipump deliver for diabetes patients?. Nature Medicine, 2022, 28, 27-28.	15.2	0
1257	FC082: Effects of Dapagliflozin in Patients with Chronic Kidney Disease According to Background Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dose. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0